

## PRODUCT MONOGRAPH

Pr **RAPAMUNE**<sup>®</sup>

**(Sirolimus Oral Solution and Tablets)**

**Oral Solution: 1mg/mL; Tablets: 1 mg, 2 mg and 5 mg**

**Professed**

**Immunosuppressive agent**

<sup>®</sup>T.M. Wyeth.  
Pfizer Canada Inc., Licensee  
17,300 Trans-Canada Highway  
Kirkland, Quebec H9J 2M5

**Date of Revision:**  
25 October 2017

**Control Number: 208129**

<sup>©</sup>Pfizer Canada Inc.

## TABLE OF CONTENTS

PART I: HEALTH PROFESSIONAL INFORMATION.....	3
SUMMARY PRODUCT INFORMATION.....	3
INDICATIONS AND CLINICAL USE .....	3
CONTRAINDICATIONS.....	4
WARNINGS AND PRECAUTIONS .....	4
ADVERSE REACTIONS .....	13
DRUG INTERACTIONS .....	25
DOSAGE AND ADMINISTRATION .....	30
OVERDOSAGE.....	35
ACTION AND CLINICAL PHARMACOLOGY .....	36
STORAGE AND STABILITY .....	46
SPECIAL HANDLING INSTRUCTIONS.....	46
DOSAGE FORMS, COMPOSITION AND PACKAGING.....	47
PART II: SCIENTIFIC INFORMATION.....	49
PHARMACEUTICAL INFORMATION .....	49
CLINICAL TRIALS .....	50
DETAILED PHARMACOLOGY .....	62
TOXICOLOGY.....	64
REFERENCES.....	68
PART III: CONSUMER INFORMATION.....	72

**Rapamune®**  
**(Sirolimus Oral Solution and Tablets)**

**PART I: HEALTH PROFESSIONAL INFORMATION**

**SUMMARY PRODUCT INFORMATION**

<b>Route of Administration</b>	<b>Dosage Form / Strength</b>	<b>Clinically Relevant Nonmedicinal Ingredients</b>
Oral	Solution: 1 mg/mL	Ethanol
Oral	Tablets: 1 mg, 2 mg and 5 mg	Lactose Monohydrate  <i>For a complete listing see DOSAGE FORMS, COMPOSITION AND PACKAGING section.</i>

**INDICATIONS AND CLINICAL USE**

Rapamune (sirolimus oral solution and tablets) is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal transplants:

- ***In patients at low to moderate immunological risk***, it is recommended that Rapamune be used initially in a regimen with cyclosporine and corticosteroids. Cyclosporine should be withdrawn 2 to 4 months after transplantation and the Rapamune dose should be increased to reach recommended blood concentrations (See DOSAGE AND ADMINISTRATION).
- ***In patients at high immunologic risk*** (defined as Black transplant recipients and/or repeat renal transplant recipients who lost a previous allograft for immunologic reason and/or patients with high-panel reactive antibodies (PRA; peak PRA level > 80%), it is recommended that Rapamune be used in combination with cyclosporine and corticosteroids for the first year following transplantation (See DOSAGE AND ADMINISTRATION and CLINICAL TRIALS). Thereafter, any adjustments to the immunosuppressive regimen should be considered on the basis of the clinical status of the patient.

**Geriatrics (> 65 years of age):**

Clinical studies of Rapamune did not include sufficient numbers of patients aged 65 and over to determine whether safety and efficacy differ in this population from younger patients. Based on the finding that blood clearance decreases linearly with age, consideration should be given to reducing the Rapamune dose in patients 65 years of age and over.

**Pediatrics (< 13 years of age):**

**THE SAFETY AND EFFICACY OF RAPAMUNE IN PEDIATRIC PATIENTS BELOW THE AGE OF 13 YEARS HAVE NOT BEEN ESTABLISHED.**

**CONTRAINDICATIONS**

- Rapamune is contraindicated in patients with a hypersensitivity to sirolimus or its derivatives or any component\* of the drug product. \*For a complete listing, see the DOSAGE FORMS, COMPOSITION AND PACKAGING section of the Product Monograph.

**WARNINGS AND PRECAUTIONS****Serious Warnings and Precautions**

- Increased susceptibility to infection and the possible development of lymphoma may result from immunosuppression.
- Only physicians experienced in immunosuppressive therapy and management of organ transplant patients should use Rapamune. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient.
- Hypersensitivity reactions, including anaphylactic/anaphylactoid reactions, angioedema, exfoliative dermatitis, and hypersensitivity vasculitis, have been associated with the administration of sirolimus.
- The safety and efficacy of sirolimus as immunosuppressive therapy have not been established in liver or lung transplant patients, and therefore, such use is not recommended.

## **General**

Rapamune is intended for oral administration only.

Rapamune has been approved to be administered concurrently with cyclosporine (liquid and microemulsion) and corticosteroids. The efficacy and safety of the use of Rapamune in combination with other immunosuppressive agents has not been established.

## **Use in High Risk Patients**

The safety and efficacy of cyclosporine withdrawal in high-risk patients have not been adequately studied and it is therefore not recommended. This includes patients with Banff grade III acute rejection or vascular rejection prior to cyclosporine withdrawal, those who are dialysis-dependent, or with serum creatinine > 400 µmol/L (4.5 mg/dL), black patients, re-transplants, multi-organ transplants, and patients with high panel of reactive antibodies. It is recommended that Rapamune be used in combination with cyclosporine and corticosteroids for the first year following transplantation.

The safety and efficacy of this combination in high-risk renal transplant patients have not been studied beyond one year. Therefore, after the first year following transplantation any adjustments to the immunosuppressive regimen should be considered on the basis of the clinical status of the patient (See INDICATIONS AND CLINICAL USE, DOSAGE AND ADMINISTRATION, and CLINICAL TRIALS).

## **Antimicrobial Prophylaxis**

Cytomegalovirus (CMV) prophylaxis is recommended for 3 months after transplantation, particularly for patients at increased risk for CMV infection.

Cases of *Pneumocystis carinii* pneumonia have been reported in patients not receiving antimicrobial prophylaxis. Therefore, antimicrobial prophylaxis for *Pneumocystis carinii* pneumonia should be administered for 1 year following transplantation.

## **Carcinogenesis and Mutagenesis**

Patients receiving immunosuppression regimens involving combinations of drugs, including Rapamune, as part of an immunosuppression regimen are at increased risk of developing lymphomas and other malignancies, particularly of the skin. The risk appears to be related to the intensity and duration of immunosuppression rather than to the use of any specific agent. As

with all patients at an increased risk for skin cancer, exposure to sunlight and UV light should be limited by wearing protective clothing and using a sunscreen with a high protection factor.

Also, see TOXICOLOGY - Chronic Toxicology - Carcinogenicity, Mutagenesis, and Impairment of Fertility.

### **Cardiovascular**

#### **Hyperlipidemia:**

Increased serum cholesterol and triglycerides requiring treatment may occur in patients treated with Rapamune. The risk/benefit should be considered in patients with established hyperlipidemia before initiating an immunosuppressive regimen including Rapamune.

### **Endocrine and Metabolism**

Co-administration of Rapamune with strong inhibitors of CYP3A4 and/or P-glycoprotein (P-gp) (such as ketoconazole, voriconazole, itraconazole, telithromycin, or clarithromycin) or strong inducers of CYP3A4 and/or P-gp (such as rifampicin or rifabutin) is not recommended.

Sirolimus is extensively metabolized by the CYP3A4 isozyme in the intestinal wall and liver.

Inhibitors of CYP3A4 decrease the metabolism of sirolimus and increase sirolimus whole blood concentrations. Inducers of CYP3A4 increase the metabolism of sirolimus and decrease sirolimus whole blood concentrations (see DRUG INTERACTIONS).

### **Hematologic**

Patients receiving immunosuppressive agents such as Rapamune may develop leukopenia. The development of leukopenia may be related to Rapamune itself, concomitant medications, viral infection, or some combination of these causes. If leukopenia develops, dose reduction of Rapamune and/or other immunosuppressive agents should be considered.

### **Hepatic/Biliary/Pancreatic**

#### **Liver Transplantation Excess Mortality, Graft Loss, and Hepatic Artery Thrombosis (HAT):**

The use of Rapamune in combination with tacrolimus was associated with excess mortality and graft loss in a study in *de novo* liver transplant recipients. Many of these patients had evidence of infection at or near the time of death. In this and another study in *de novo* liver transplant recipients, the use of Rapamune in combination with cyclosporine or tacrolimus was associated

with an increase in HAT; most cases of HAT occurred within 30 days post-transplantation and most led to graft loss or death.

**Hepatic impairment:** When compared to normal subjects, the clearance of sirolimus is significantly decreased in patients with impaired hepatic function. Accordingly, the blood concentration of Rapamune should be closely monitored and the dose of Rapamune should be adjusted based on the blood concentration. It is not necessary to modify the loading dose (see Action and Clinical Pharmacology and Dosage and Administration).

### **Immunologic**

Oversuppression of the immune system can increase susceptibility to opportunistic infections, sepsis, and fatal infections. Mucosal herpes simplex infections were significantly more frequent in the 5 mg/day Rapamune-treated patients compared to other treatment groups (see ADVERSE REACTIONS). Activation of latent viral infections was reported, including BK virus associated nephropathy and JC virus associated progressive multifocal leukoencephalopathy (PML). These infections are often related to a high immunosuppressive burden and may lead to serious or fatal conditions. Reduction of immunosuppression should be considered for patients who develop evidence of BK virus-associated nephropathy and also in patients who develop PML.

**Vaccinations:** Immunosuppressants may affect response to vaccination (see DRUG INTERACTIONS - Vaccination).

### **Angioedema**

The concomitant administration of Rapamune and angiotensin-converting enzyme (ACE) inhibitors has resulted in angioneurotic edema-type reactions. Elevated sirolimus levels (with/without concomitant ACE inhibitors) may also potentiate angioedema. In some cases, the angioedema has resolved upon discontinuation or dose reduction of Rapamune.

### **Musculoskeletal**

**Rhabdomyolysis:** In clinical trials, the concomitant administration of Rapamune and HMG-CoA reductase inhibitors and/or fibrates was well tolerated. During Rapamune therapy with or without cyclosporine, patients should be monitored for elevated lipids, and patients administered an HMG-CoA reductase inhibitor and/or fibrate should be monitored for the possible development of rhabdomyolysis and other adverse effects as described in the respective labelling for these agents.

## **Post-Operative Complications**

mTOR inhibitors such as sirolimus have been shown in vitro to inhibit production of certain growth factors that may affect angiogenesis, fibroblast proliferation, and vascular permeability, which may be associated with impaired or delayed wound healing and/or fluid accumulation.

**Impaired Wound Healing:** Studies showed that in comparison with other immunosuppressive regimens the use of sirolimus-based immunosuppressive regimens was associated with a significantly higher incidence of wound-healing complications, including wound dehiscence, incisional herniae, anastomotic disruption, and lymphocele (see ADVERSE REACTIONS, Post-Market Adverse Drug Reactions, Metabolic: Abnormal healing). Greater post-operative measures should be taken to minimize this complication.

**Fluid Accumulation:** Use of sirolimus is associated with an increased incidence of fluid accumulation, including peripheral edema, lymphedema, pleural effusion and pericardial effusions (including hemodynamically significant effusions in children and adults).

## **Renal**

**Renal function:** Patients treated with cyclosporine and Rapamune were noted to have higher serum creatinine levels, lower glomerular filtration rates, and a more rapid rate of decline in renal function compared with patients treated with cyclosporine and placebo or azathioprine controls (Studies 1 and 2) or patients continuing treatment with Rapamune following withdrawal of cyclosporine (Rapamune Maintenance Regimen: Study 4). In the Rapamune Maintenance Regimen Study that compared a regimen of Rapamune, cyclosporine and steroids to one in which cyclosporine was withdrawn 2-4 months post-transplantation, those in whom cyclosporine was not withdrawn had significantly higher serum creatinine levels and significantly lower glomerular filtration rates at 12 months through 60 months, and significantly lower graft survival at 48 months, the point at which it was decided by the sponsor to discontinue subjects from assigned therapy in the Rapamune and cyclosporine arm. When the protocol was amended all subjects had reached 48 months and some completed the 60 months of the study. In patients at low to moderate immunologic risk continuation of combination therapy with cyclosporine beyond 4 months following transplantation should only be considered when the benefits outweigh the risks of this combination for the individual patients (See CLINICAL TRIALS - Rapamune Maintenance Regimen).

Renal function should be closely monitored during the administration of Rapamune in combination with cyclosporine. Appropriate adjustments of the immunosuppressive regimen,

including discontinuation of cyclosporine and /or Rapamune should be considered in patients with elevated or increasing serum creatinine levels. Caution should be exercised when using agents (e.g., aminoglycosides and amphotericin B) that are known to have a deleterious effect on renal function.

In patients with delayed graft function, Rapamune may delay recovery of renal function.

**Proteinuria:** In a study evaluating conversion from calcineurin inhibitors to sirolimus in maintenance renal transplant patients 6 – 120 months post-transplant, conversion was associated with significantly increased urinary protein excretion. Periodic quantitative monitoring of urinary protein excretion is recommended. The safety and efficacy of conversion from calcineurin inhibitors to sirolimus in maintenance renal transplant population has not been established.

**De novo use without calcineurin inhibitor (CNI):** The safety and efficacy of de novo use of Rapamune, mycophenolate mofetil (MMF), and corticosteroids, in combination with interleukin-2 receptor antibody induction is not established and is not recommended in de novo renal transplant patients (See CLINICAL TRIALS).

**Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura/thrombotic microangiopathy (HUS/TTP/TMA):** The concomitant use of sirolimus with a calcineurin inhibitor may increase the risk of calcineurin inhibitor-induced HUS/TTP/TMA.

### **Respiratory**

**Lung Transplantation - Bronchial Anastomotic Dehiscence:** Cases of bronchial anastomotic dehiscence, most fatal, have been reported in *de novo* lung transplant patients when Rapamune has been used as part of an immunosuppressive regimen.

**Interstitial Lung Disease:** Cases of interstitial lung disease [including pneumonitis, and infrequently bronchiolitis obliterans organizing pneumonia (BOOP) and pulmonary fibrosis], some fatal, with no identified infectious etiology have occurred in patients receiving immunosuppressive regimens including sirolimus. In some cases, the interstitial lung disease has resolved upon discontinuation or dose reduction of sirolimus. The risk may be increased as the sirolimus trough concentration increases.

## **Sexual Function/Reproduction**

See TOXICOLOGY - Chronic Toxicology - Carcinogenicity, Mutagenesis, and Impairment of Fertility.

## **Special Populations**

### **Pregnant Women:**

Because sirolimus is embryo/fetal toxic in rats at dosages of 0.1 mg/kg and above (approximately 1.4 times the maximum recommended human dose [MRHD]), it may cause fetal harm when administered to pregnant women. In animal studies, embryo/fetal toxicity was manifested as mortality and reduced fetal weights (with associated delays in skeletal ossification). However, no teratogenesis was evident. There were no effects on rabbit development at the maternally toxic dosage of 0.05 mg/kg (approximately 0.7 times the MRHD).

There are no adequate and well-controlled studies of Rapamune use in pregnant women. Consequently, use of Rapamune during pregnancy should be considered only if the potential benefit outweighs the potential risk to the embryo/fetus.

Effective contraception must be used before beginning Rapamune therapy, during Rapamune therapy and for 12 weeks after Rapamune has been stopped.

National Transplant Pregnancy Registry: This registry monitors maternal-fetal outcomes of pregnant women exposed to Sirolimus. Physicians are encouraged to register patients by calling 1-215-599-2078 or Toll-Free 1-877-955-6877

### **Nursing Women:**

Studies in rats have shown that sirolimus is excreted in milk. It is not known whether sirolimus is excreted in human milk. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

### **Pediatrics (<13 years of age):**

The safety and efficacy of Rapamune in pediatric patients have not been established. Therefore, Rapamune is not recommended for use in pediatric renal transplant patients.

Safety and efficacy information from a controlled clinical trial in pediatric and adolescent (<18 years of age) renal transplant recipients judged to be at **high immunologic risk**, defined as a

history of one or more acute rejection episodes and/or the presence of chronic allograft nephropathy, do not support the chronic use of the combination of Rapamune oral solution or tablets in combination with calcineurin inhibitors and corticosteroids, due to the increased risk of lipid abnormalities and deterioration of renal function associated with these immunosuppressive regimens, without increased benefit with respect to acute rejection, graft survival, or patient survival.

### **Geriatrics (> 65 years of age):**

Clinical studies of Rapamune did not include sufficient numbers of patients aged 65 and over to determine whether safety and efficacy differ in this population from younger patients. Based on the finding that blood clearance decreases linearly with age, consideration should be given to reducing the Rapamune dose in patients 65 years of age and over.

### **Monitoring and Laboratory Tests**

**Blood Concentration Monitoring:** Whole blood trough concentrations of sirolimus should be monitored in patients receiving concentration-controlled Rapamune. Monitoring is also necessary in patients likely to have altered drug metabolism; in patients with hepatic impairment; in pediatric patients; during concurrent administration of inhibitors and inducers of CYP3A4 and P-glycoprotein; and if the cyclosporine dosage is markedly changed or discontinued. It is recommended that a whole blood trough concentration be measured 1 to 2 weeks after altering the total daily dose of Rapamune, after switching between the solution and the tablet formulation, or switching from one tablet strength (1 mg, 2 mg or 5 mg) to another, to confirm that the trough concentration is within the desired target range.

In controlled clinical trials, with concomitant cyclosporine (Studies 1 and 2), mean sirolimus whole blood trough concentrations through month 6 following transplantation, expressed as chromatographic assay value, were approximately 7.2 ng/mL (range 3.6-11 ng/mL [10th to 90th percentile]) for the 2 mg/day treatment group (n=226), and 14 ng/mL (range 8.0-22 ng/mL [10th to 90th percentile]) for the 5 mg/day dose (n=219; values were obtained using a research immunoassay, but are expressed as chromatographic equivalent values, using a +20% bias for the immunoassay).

In a controlled clinical trial with cyclosporine withdrawal (Study 4), the mean sirolimus whole blood trough concentrations during months 4 through 12 following transplantation, expressed as chromatographic assay values, were approximately 8.6 ng/mL (range 5.2-12 ng/mL [10th to 90th percentile]) in the concomitant Rapamune, cyclosporine and corticosteroid treatment group (n =

205) and were 19 ng/mL (range 14-24 ng/mL [10th to 90th percentile]) in the Rapamune maintenance group after withdrawal of cyclosporine (n=201). By month 60, the mean sirolimus whole blood trough concentrations remained stable in the concomitant Rapamune, cyclosporine and corticosteroid group (n=71) at 8.6 ng/mL (range 5.0 to 12 ng/mL [10th to 90th percentile]). For the cyclosporine withdrawal group (n=104) by month 60, the mean sirolimus whole blood concentration had fallen to 15 ng/mL (range 9.4 to 19 ng/mL [10th to 90th percentile]).

In a concentration-controlled clinical trial in high-risk adult patients (Study 5), the mean whole blood sirolimus trough concentrations, during months 9 through 12 months following transplantation, as measured by chromatography, were 11.2 ng/mL (range 6.8 – 15.9 ng/mL [10<sup>th</sup> to 90<sup>th</sup> percentile]) (n=127), and the mean whole blood trough concentrations of cyclosporine were 133 ng/mL (range 54 – 215 ng/mL [10<sup>th</sup> to 90<sup>th</sup> percentile]).

Results from other assays may differ from those with an immunoassay. On average, chromatographic methods [high-performance liquid chromatography with ultraviolet detection (HPLC UV) or liquid chromatography with tandem mass spectrometric detection (LC/MS/MS)] yield results that are approximately 20% (range 10%-29%) lower than the immunoassay whole blood concentration determinations. The recommended 24-hour trough concentration ranges for sirolimus are based on chromatographic methods. Several assay methodologies have been used to measure the whole blood concentrations of sirolimus. Currently in clinical practice, sirolimus whole blood concentrations are being measured by both chromatographic and immunoassay methodologies. The concentration values obtained by these different methodologies are not interchangeable. Adjustments to the targeted range should be made according to the assay being utilized to determine the sirolimus trough concentration. A discussion of different assay methods is contained in *Clinical Therapeutics* 2000; 22 Suppl B:B1-B132. Since assay results are also laboratory dependent, adjustment to the targeted therapeutic range must be made with a detailed knowledge of the site-specific assay used.

**Lipids:** The use of Rapamune may lead to increased serum cholesterol and triglycerides that may require treatment. Patients must be monitored for hyperlipidemia. In studies 1 and 2, high fasting triglyceride levels (>11.3 mmol/L [1000 mg/dL]) were observed in 0.8% of patients receiving Rapamune 2 mg/day and 3% of patients receiving Rapamune 5 mg/day. Monitoring of triglycerides should be included as part of routine post-transplant patient management, particularly in patients with antecedent dyslipidemia. Elevated triglycerides can be managed by appropriate medical therapy, dose reduction or, for severe elevations, discontinuation of Rapamune.

In Study 4 during the pre-randomization period, mean fasting serum cholesterol and triglyceride values rapidly increased with the administration of Rapamune, and peaked at 2 months with mean cholesterol values > 6.2 mmol/L (240 mg/dL) and triglycerides > 2.8 mmol/L (250 mg/dL). After 3 years of treatment with Rapamune, mean fasting cholesterol (5.9 versus 6.3 mmol/L; p=0.059) trended higher in the cyclosporine withdrawal arm, whereas HDL cholesterol, LDL cholesterol, and triglycerides were similar in the two groups.

## **ADVERSE REACTIONS**

### **Adverse Drug Reaction Overview**

- Increased susceptibility to infection and the possible development of lymphoma may result from immunosuppression.
- Clostridium difficile enterocolitis has been reported in patients receiving sirolimus.
- Hypersensitivity reactions, including anaphylactic/anaphylactoid reactions, angioedema, exfoliative dermatitis, and hypersensitivity vasculitis, have been associated with the administration of sirolimus.

### **Clinical Trial Adverse Drug Reactions**

*Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.*

### **Rapamune and cyclosporine combination therapy:**

**Rapamune Oral Solution:** The incidence of adverse reactions was determined in two randomized, double-blind, multicentre controlled trials (Studies 1 and 2) in which 499 renal transplant patients received Rapamune (sirolimus oral solution) 2 mg/day, 477 received Rapamune oral solution 5 mg/day, 160 received azathioprine 2-3 mg/kg/day, and 124 received placebo. All patients were treated with cyclosporine and corticosteroids.

Adverse reactions associated with the administration of Rapamune which occurred at a significantly higher frequency than placebo or azathioprine control group include arthralgia, hirsutism, diarrhea, hypertension, hypokalemia, lymphocele, peripheral edema, rash, tachycardia, and some infections. In general, adverse events related to administration of Rapamune were dependent on dose/concentration. Dose related elevations of triglycerides and cholesterol and decreases in platelets and hemoglobin have occurred in patients receiving Rapamune.

The data presented by study group in Table 1 show the adverse reactions that occurred in any treatment group with an incidence of  $\geq 10\%$ .

**Table -1: ADVERSE EVENTS OCCURRING AT A FREQUENCY OF  $\geq 10\%$  IN ANY TREATMENT GROUP IN PREVENTION OF ACUTE RENAL REJECTION TRIALS (%) AT 12 MONTHS POST-TRANSPLANTATION FOR STUDIES 1 AND 2<sup>a</sup>**

Body system Adverse Event	Rapamune Oral Solution		Rapamune Oral Solution		Azathioprine	Placebo
	2 mg/day		5 mg/day		2-3 mg/kg/day	
	Study 1 (n = 281)	Study 2 (n = 218)	Study 1 (n = 269)	Study 2 (n = 208)	Study 1 (n = 160)	Study 2 (n = 124)
<b>Body as a whole</b>						
Abdomen enlarged	15	8	9	13	9	10
Abdominal pain	20	26	24	31	22	23
Accidental injury	8	11	9	8	9	10
Asthenia	27	17	32	23	23	19
Back pain	13	20	21	15	19	17
Chest pain	10	16	15	18	12	16
Chills	7	5	8	12	2	8
Face edema	5	5	11	10	4	4
Fever	19	18	22	27	19	23
Headache	18	30	23	30	10	20
Lymphocele	12	11	15	13	3	6
Overdose	10	17	11	17	6	10
Pain	19	29	25	23	20	21
Transplant rejection	2	3	3	7	3	15
<b>Cardiovascular system</b>						
Hypertension	38	39	34	43	23	41
Tachycardia	10	10	12	12	4	4
Hypotension	3	4	8	4	10	6
<b>Digestive system</b>						
Constipation	25	34	30	34	34	28
Diarrhea	20	18	32	28	14	14
Dyspepsia	12	21	20	22	21	25
Liver function tests abnormal	9	7	11	11	9	7
Nausea	25	21	28	25	31	22
Vomiting	16	17	17	18	25	16
<b>Endocrine system</b>	15	15	20	20	12	15

**Table -1: ADVERSE EVENTS OCCURRING AT A FREQUENCY OF  $\geq 10\%$  IN ANY TREATMENT GROUP IN PREVENTION OF ACUTE RENAL REJECTION TRIALS (%) AT 12 MONTHS POST-TRANSPLANTATION FOR STUDIES 1 AND 2<sup>a</sup>**

Body system Adverse Event	Rapamune Oral Solution		Rapamune Oral Solution		Azathioprine	Placebo
	2 mg/day		5 mg/day		2-3 mg/kg/day	
	Study 1 (n = 281)	Study 2 (n = 218)	Study 1 (n = 269)	Study 2 (n = 208)	Study 1 (n = 160)	Study 2 (n = 124)
<b>Hemic and lymphatic system</b>						
Anemia	21	18	31	28	22	14
Leukopenia	6	7	12	9	12	2
Echymosis	5	6	6	12	7	3
Thrombocytopenia	10	12	18	24	7	3
<b>Metabolic and nutritional</b>						
Creatinine increased	28	32	28	38	22	33
Edema	20	17	14	14	15	7
Healing abnormal	8	7	10	12	4	6
Hypercholesterolemia	33	41	37	46	24	20
Hyperglycemia	13	11	16	14	13	10
Hyperkalemia	13	14	10	12	19	23
Hyperlipemia	34	42	42	55	24	20
Hypokalemia	12	7	17	15	9	6
Hypophosphatemia	16	14	21	17	18	18
Lactic dehydrogenase increased	10	11	13	18	6	5
Peripheral edema	53	48	56	51	48	42
Weight gain	17	8	11	6	13	13
<b>Musculoskeletal system</b>						
Arthralgia	18	21	23	25	13	15
<b>Nervous system</b>						
Dizziness	10	9	13	13	11	8
Hypesthesia	5	7	7	10	6	5
Insomnia	10	10	20	11	13	8
Tremor	23	17	26	17	18	11
Paresthesia	7	10	8	9	4	6
<b>Respiratory system</b>						
Cough increased	14	8	16	15	13	17
Dyspnea	17	20	22	24	14	23
Epistaxis	4	4	6	11	<1	0
Pulmonary physical finding	9	13	11	11	5	12
Rhinitis	12	11	14	13	8	8
<b>Skin and appendages</b>						
Acne	25	19	19	19	11	14
Rash	10	5	9	15	2	5
Hirsutism	5	8	12	8	3	8
<b>Special senses</b>						
Abnormal vision	9	8	11	12	8	6
<b>Urogenital system</b>						
Dysuria	9	10	13	17	10	6
Hematuria	11	14	15	17	13	9
Oliguria	5	4	4	7	6	10

**Table -1: ADVERSE EVENTS OCCURRING AT A FREQUENCY OF  $\geq 10\%$  IN ANY TREATMENT GROUP IN PREVENTION OF ACUTE RENAL REJECTION TRIALS (%) AT 12 MONTHS POST-TRANSPLANTATION FOR STUDIES 1 AND 2<sup>a</sup>**

Body system Adverse Event	Rapamune Oral Solution 2 mg/day		Rapamune Oral Solution 5 mg/day		Azathioprine 2-3 mg/kg/day	Placebo
	Study 1 (n = 281)	Study 2 (n = 218)	Study 1 (n = 269)	Study 2 (n = 208)	Study 1 (n = 160)	Study 2 (n = 124)
Kidney tubular necrosis	9	9	10	10	7	4
<b>Study event associated with miscellaneous factors</b>	41	37	42	40	34	35
<b>Local reaction to procedure</b>	40	37	42	40	34	34

a: All patients in Study 1 and 2 received cyclosporine and corticosteroids.

Table 2 summarizes the incidence rates at 6 months for clinically important opportunistic or common transplant-related infections across treatment groups Studies 1 and 2. There were no significant differences in incidence rates between treatment groups, with the exception of mucosal infections with Herpes simplex, which occurred at a significantly greater rate in patients treated with Rapamune 5 mg/day.

**Table -2: INCIDENCE (%) OF SELECTED CLINICALLY IMPORTANT INFECTIONS IN PREVENTION OF ACUTE RENAL REJECTION FOR STUDIES 1 AND 2<sup>a,b</sup>**

Infection	Sirolimus 2 mg/day (n=511)	Sirolimus 5 mg/day (n=493)	Azathioprine 2-3 mg/kg/day (n=161)	Placebo (n=130)
Sepsis	6.3	6.7	3.7	6.9
CMV Infection (generalized)	2.9	4.1	3.7	5.4
CMV Infection (tissue-invasive)	0.4	1.0	1.2	0.8
Pneumonia	2.5	4.3	1.2	3.9
<i>Pneumocystis carinii</i> pneumonia	0.4	0	0	0
Herpes Simplex	5.3	12.2	3.7	6.2
Herpes Zoster	1.8	2.2	1.9	3.1
Urinary Tract Infection/Pyelonephritis	19.8	23.1	23	21.5
Wound Infection	6.5	8.3	5.0	6.9
Epstein-Barr Virus	0.6	0.6	0	0

a: Analysis performed on the intent-to-treat patient populations

b: All patients in Study 1 and 2 received cyclosporine and corticosteroids

Table 3 summarizes the incidence of malignancies in Studies 1 and 2. At 12 months following transplantation there was a very low incidence of malignancies and there were no significant differences between treatment groups.

**Table -3: INCIDENCE (%) OF MALIGNANCY (STUDIES 1 AND 2 COMBINED, 12 MONTHS)**

Malignancy	Rapamune 2 mg/day (n = 511)	Rapamune 5 mg/day (n = 493)	Placebo (n = 130)	Azathioprine (n = 161)
Lymphoma/PTLD <sup>a,b</sup>	0.4	1.4	0	0.6
Skin (excluding melanoma) <sup>c</sup>	0.4	1.4	3.1	1.2
Other	0.6	0.6	0	0

a: Lymphoma/Post-transplant lymphoproliferative disorder.

b:  $p > 0.05$  across treatment groups.

c:  $p < 0.05$ , placebo vs Rapamune 2 mg/day.

The following reactions (listed alphabetically by body system) were reported with a  $\geq 1\%$  incidence in patients treated with Rapamune in combination with cyclosporine and corticosteroids:

In general, adverse events related to administration of Rapamune were dependent on dose/concentration.

Body as a whole: Lymphocele, peripheral edema, generalized edema, hernia, hormone level altered, lab test abnormal, malaise, pelvic pain, abnormal healing, fever, fungal, viral and bacterial infections (such as Mycobacterial infections, Epstein-Barr virus, CMV, and Herpes zoster), herpes simplex, sepsis

Cardiovascular system: Arterial anomaly, cardiomegaly, cardiovascular physical finding, congestive heart failure, hemorrhage, hypervolemia, palpitation, peripheral vascular disorder, postural hypotension, thrombophlebitis, thrombosis, vascular disorder, vasodilatation, venous thromboembolism (including pulmonary embolism, deep vein thrombosis), tachycardia

Digestive system:	Anorexia, eructation, esophagitis, flatulence, gingivitis, gum hyperplasia, ileus, increased appetite, mouth ulceration, rectal disorder, stomatitis, abdominal pain, diarrhea
Endocrine system:	Cushing's syndrome, diabetes mellitus, glycosuria, parathyroid disorder
Hemic and lymphatic system:	Leukocytosis, neutropenia, polycythemia, thrombotic thrombocytopenic purpura/hemolytic uremic syndrome, anemia, leukopenia, thrombocytopenia
Metabolic and Nutritional:	Acidosis, alkaline phosphatase increased, bilirubinemia, urea/BUN increased, creatine phosphokinase increased, dehydration, hypercalcemia, hypophosphatemia, hypocalcemia, hyperglycemia, hypomagnesemia, hyponatremia, hypoproteinemia, AST/SGOT increased, ALT/SGPT increased, weight loss, hypercholesterolemia, hypertriglyceridemia (hyperlipemia), hypokalemia, increased lactic dehydrogenase (LDH)
Musculoskeletal system:	Bone necrosis, bone pain, joint disorder, leg cramps, myalgia, osteoporosis, tetany, arthralgia
Nervous system:	Agitation, anxiety, circumoral paresthesia, confusion, depression, hallucinations, hypertonia, hypesthesia, hypotonia, nervousness, neuropathy, somnolence
Respiratory system:	Asthma, atelectasis, hemoptysis, hiccup, hypoxia, lung edema, pharyngitis, pleural effusion, pneumonitis, sinusitis, epistaxis, pneumonia
Skin and appendages:	Nail disorder, pruritus, skin benign neoplasm, skin disorder, skin hypertrophy, skin ulcer, sweating, acne, rash, squamous cell carcinoma, basal cell carcinoma, neuroendocrine carcinoma of the skin
Special senses:	Cataract specified, conjunctivitis, ear pain, tinnitus

Urogenital system: Albuminuria, bladder pain, hydronephrosis, impotence, kidney function abnormal, kidney pain, nocturia, scrotal edema, testis disorder, toxic nephropathy, urinary frequency, urinary incontinence, urinary retention, urinary tract disorder, urine abnormality, urinary tract infection, pyelonephritis, proteinuria, ovarian cysts; menstrual disorders (including amenorrhea and menorrhagia)

Less frequently occurring adverse events included: pancreatitis, lymphoma/post-transplant lymphoproliferative disorder, pancytopenia, melanoma, exfoliative dermatitis (See WARNINGS AND PRECAUTIONS), nephrotic syndrome, pulmonary hemorrhage, and pericardial effusion (including hemodynamically significant effusions in children and adults).

**Rapamune Tablets:**

The incidence of adverse reactions through 12 months was determined in a randomized, multicentre, controlled trial (Study 3) in which 229 renal transplant patients received Rapamune Oral Solution 2 mg once daily and 228 patients received Rapamune Tablets 2 mg once daily. All patients were treated with cyclosporine and corticosteroids.

The adverse reactions that occurred in either treatment group with an incidence of  $\geq 10\%$  in Study 3 were similar to those reported for Studies 1 and 2. There was no notable difference in the incidence of these adverse events between treatment groups (oral solution versus tablets) in Study 3, with the exception of acne and pharyngitis, which occurred more frequently in the oral solution group, and liver function abnormal and tremor which occurred more frequently in the tablet group.

The adverse events that occurred in patients with an incidence of  $\geq 3\%$  and  $< 10\%$  in either treatment group in Study 3 were similar to those reported in Studies 1 and 2. There was no notable difference in the incidence of these adverse events between treatment groups (oral solution versus tablets) in Study 3, with the exception of hypertonia and urinary incontinence, which occurred more frequently in the oral solution group and cataract, acidosis, ascites, and dysphagia which occurred more frequently in the tablet group. In Study 3 alone, menorrhagia, metrorrhagia, and polyuria occurred with an incidence of  $\geq 3\%$  and  $< 10\%$ .

The clinically important opportunistic or common transplant-related infections were identical in all three studies and the incidences of these infections were similar in Study 3 compared with

Studies 1 and 2. The incidence rates of these infections were not significantly different between the oral solution and tablet treatment groups in Study 3.

In Study 3, there were two cases of lymphoma or lymphoproliferative disorder in the oral solution treatment group (0.8%) and two reported cases of lymphoma or lymphoproliferative disorder in the tablet treatment group (0.8%). These differences were not statistically significant and were similar to the incidences observed in Studies 1 and 2.

**Rapamune Maintenance Regimen (RMR):** The incidence of adverse reactions was determined through 60 months in a randomized, multicentre controlled trial (Study 4). This study compared 430 renal transplant patients who were administered Rapamune, cyclosporine and corticosteroids for the first 3 months after transplantation (pre-randomization period) followed by a 1:1 randomization at 3 months  $\pm$  2 weeks to the withdrawal of cyclosporine (Rapamune maintenance regimen) or the continuation of the Rapamune, cyclosporine and steroid regimen. The safety profile prior to randomization (start of cyclosporine withdrawal) was similar to that of the 2 mg Rapamune groups in Studies 1, 2, and 3.

Patients who had cyclosporine eliminated from their immunosuppressive therapy at 3 months  $\pm$  2 weeks experienced significantly higher incidences of increased AST/SGOT and increased ALT/SGPT, liver damage, hypokalemia, thrombocytopenia, abnormal healing, acne, ileus, and joint disorder. Conversely, the incidence of acidosis, hypertension, cyclosporine toxicity, increased creatinine, abnormal kidney function, toxic nephropathy, edema, hyperkalemia, hyperuricemia, gout, benign skin neoplasm and gum hyperplasia was significantly higher in patients who remained on a Rapamune plus cyclosporine regimen. Mean systolic and diastolic blood pressure improved significantly following cyclosporine withdrawal.

The incidence of Herpes zoster infection (at 60 months) was significantly lower in patients receiving Rapamune following cyclosporine withdrawal compared with patients who continued to receive Rapamune and cyclosporine.

The incidence of malignancies in at 60 months post-transplant following cyclosporine withdrawal, is presented in Table 4. The incidence of lymphoma or lymphoproliferative disease was similar in all treatment groups. The overall incidence of malignancy, based upon the number of patients who had one or more malignancy, was lower in patients receiving Rapamune as part of the Rapamune maintenance regimen as compared with patients receiving Rapamune and cyclosporine (10.7% versus 15.8%, respectively;  $p=0.155$ ).

**Table -4: INCIDENCE (%) OF MALIGNANCIES IN STUDY 4 AT 60 MONTHS POST-TRANSPLANT<sup>a</sup>**

Malignancy <sup>d</sup>	Nonrandomized <sup>b</sup> (n=95)	Rapamune with Cyclosporine Therapy <sup>c</sup> (n=215)	Rapamune Following Cyclosporine Withdrawal <sup>c</sup> (n=215)
Lymphoma/lymphoproliferative disease	1.1	1.4	0.5
Skin Carcinoma			
Non-melanoma skin carcinoma	5.3	8.8	7.0
Melanoma	0.0	0.5	0.5
Other Malignancy	5.3	7.0	3.3

a: Includes patients who prematurely discontinued treatment.

b: Patients received Rapamune, cyclosporine and corticosteroids.

c: Patients received Rapamune and corticosteroids.

d: Patients may be counted in more than one category.

**High-Risk Patients Study:** Safety was assessed in a controlled trial (Study 5) (See CLINICAL TRIALS) in 224 patients who received at least one dose of sirolimus with cyclosporine. Overall, the incidence and nature of adverse events was similar to those seen in previous combination studies with Rapamune. The incidence of malignancy was 1.3% at 12 months.

Table 5 shows the adverse reactions that occurred with an incidence of  $\geq 10\%$ .

**Table -5: Number (%) of Subjects Reporting Treatment-Emergent Adverse Events With An Incidence  $\geq 10\%$  For Study 5.**

Body System <sup>a</sup>	SRL + CsA (n = 224)
<b>Adverse Event, Preferred Term</b>	
<b>Body as a whole</b>	
Abdominal pain	73 (32.6)
Asthenia	67 (29.9)
Back pain	34 (15.2)
Chest pain	36 (16.1)
Chills	28 (12.5)
Fever	93 (41.5)
Headache	57 (25.4)
Infection	48 (21.4)
Lymphocele	61 (27.2)
Overdose	32 (14.3)
Pain	88 (39.3)
<b>Cardiovascular system</b>	
Cardiovascular physical finding	24 (10.7)
Hypertension	130 (58.0)
Hypervolemia	38 (17.0)
Hypotension	43 (19.2)
Tachycardia	48 (21.4)

**Table -5: Number (%) of Subjects Reporting Treatment-Emergent Adverse Events With An Incidence  $\geq 10\%$  For Study 5.**

<b>Body System<sup>a</sup></b>	<b>SRL + CsA</b>
Adverse Event, Preferred Term	(n = 224)
<b>Digestive system</b>	
Abdominal distension	45 (20.1)
Anorexia	24 (10.7)
Constipation	75 (33.5)
Diarrhea	80 (35.7)
Dyspepsia	25 (11.2)
Liver function tests abnormal	31 (13.8)
Nausea	99 (44.2)
Vomiting	73 (32.6)
<b>Endocrine system</b>	
Diabetes mellitus	28 (12.5)
<b>Hemic and lymphatic system</b>	
Anemia	137 (61.2)
Leukopenia	78 (34.8)
Thrombocytopenia	55 (24.6)
<b>Metabolic and nutritional system</b>	
Acidosis	54 (24.1)
Creatinine increased	89 (39.7)
Edema	59 (26.3)
Healing abnormal	49 (21.9)
Hypercholesterolemia	58 (25.9)
Hyperglycemia	65 (29.0)
Hyperkalemia	71 (31.7)
Hyperlipemia	97 (43.3)
Hyperphosphatemia	23 (10.3)
Hypocalcemia	39 (17.4)
Hypokalemia	53 (23.7)
Hypomagnesemia	50 (22.3)
Hypophosphatemia	78 (34.8)
Peripheral edema	156 (69.6)
Weight gain	45 (20.1)
Weight loss	24 (10.7)
<b>Musculoskeletal system</b>	
Arthralgia	47 (21.0)
<b>Nervous system</b>	
Dizziness	38 (17.0)
Insomnia	45 (20.1)
Tremor	35 (15.6)
<b>Respiratory system</b>	
Cough increased	46 (20.5)
Dyspnea	75 (33.5)
Lung edema	24 (10.7)
Pharyngitis	35 (15.6)
Pneumonia	17 (7.6)
Pulmonary physical finding	42 (18.8)
Rhinitis	49 (21.9)
Upper respiratory infection	33 (14.7)
<b>Skin and appendages</b>	
Acne	42 (18.8)
Pruritus	22 (9.8)

**Table -5: Number (%) of Subjects Reporting Treatment-Emergent Adverse Events With An Incidence  $\geq 10\%$  For Study 5.**

<b>Body System<sup>a</sup></b>	<b>SRL + CsA</b>
Adverse Event, Preferred Term	(n = 224)
<b>Urogenital system</b>	
Dysuria	40 (17.9)
Hematuria	49 (21.9)
Impotence <sup>b</sup>	16 (12.7)
Kidney tubular necrosis	103 (46.0)
Urinary frequency	25 (11.2)
Urinary tract disorder	26 (11.6)
Urinary tract infection	67 (29.9)
<b>Treatment-emergent adverse event associated with miscellaneous factors</b>	
Local reaction to procedure	133 (59.4)

a: A subject may have reported 2 or more different adverse events in the same body system.

b: Sex-related event; the percentage is calculated using as the denominator the number of men in group I (120) or group II (126).

Abbreviations: CsA = cyclosporine; SRL = sirolimus

### **Other Clinical Trial Adverse Drug Reactions**

Safety was assessed in a controlled clinical trial in pediatric (< 18 years of age) renal transplant patients considered high immunologic risk, defined as a history of one or more acute allograft rejection episodes and/or the presence of chronic allograft nephropathy on a renal biopsy. The use of Rapamune in combination with calcineurin inhibitors and corticosteroids was associated with an increased risk of deterioration of renal function, serum lipid abnormalities (including but not limited to increased serum triglycerides and cholesterol), and urinary tract infections.

The safety and efficacy of conversion from calcineurin inhibitors to Rapamune in maintenance renal transplant patients have not been established. In a study evaluating the safety and efficacy of conversion (6 to 120 months after transplantation) from calcineurin inhibitors to Rapamune (sirolimus target levels of 12 - 20 ng/mL by chromatographic assay) in maintenance renal transplant patients 6 months – 10 years post-transplant, enrollment was stopped in the subset of patients (n=90) with a baseline glomerular filtration rate of less than 40 mL/min. There was a higher rate of serious adverse events including pneumonia, acute rejection, graft loss and death in this Rapamune treatment arm (n=60, median time post-transplant 36 months).

In a study evaluating the safety and efficacy of conversion from tacrolimus to Rapamune 3 to 5 months post renal transplant, a higher rate of acute rejection and new onset diabetes mellitus was observed following conversion to Rapamune (see Pharmacodynamics).

The concomitant use of Rapamune with a calcineurin inhibitor may increase the risk of calcineurin inhibitor-induced hemolytic uremic syndrome/thrombotic thrombocytopenic purpura/thrombotic microangiopathy.

In patients with delayed graft function, Rapamune may delay recovery of renal function (See WARNINGS AND PRECAUTIONS, Renal function).

### **Abnormal Hematologic and Clinical Chemistry Findings**

Abnormal hematologic and clinical chemistry findings are included in Clinical Trials Adverse Reactions (see previous section).

### **Post-Market Adverse Drug Reactions**

Reporting rates determined on the basis of spontaneously reported post-marketing adverse events are generally presumed to underestimate the risks associated with drug treatments.

The following adverse events have been reported spontaneously during post-marketing experience with Rapamune. A causal relationship to Rapamune cannot be excluded for spontaneously reported events.

**Body as a Whole:** Lymphedema, tuberculosis

**Cardiovascular System:** Pericardial effusion (including hemodynamically significant effusions in children and adults).

**Digestive:** Ascites reports have been common. Clostridium difficile enterocolitis has been reported in patients receiving sirolimus.

**Hemic and Lymphatic System:** Pancytopenia

**Hepatobiliary Disorders:** Hepatotoxicity has been reported, including fatal hepatic necrosis with elevated trough sirolimus concentrations (i.e., exceeding therapeutic levels).

**Immune System:** Hypersensitivity reactions, including anaphylactic /anaphylactoid reactions, angioedema, exfoliative dermatitis, and hypersensitivity vasculitis, have been associated with the administration of sirolimus (see WARNINGS AND PRECAUTIONS).

**Metabolic and Nutritional:** Fluid accumulation reports have been common.

**Musculoskeletal:** Rhabdomyolysis has been reported in patients administered Rapamune with HMG-CoA reductase inhibitors, with or without cyclosporine (See WARNINGS AND PRECAUTIONS – Special Populations - Musculoskeletal).

**Nerve system disorders:** There have been cases of posterior reversible encephalopathy syndrome (PRES) reported with the use of immunosuppressants, including sirolimus.

**Respiratory System:** Cases of interstitial lung disease [including pneumonitis, and infrequently bronchiolitis obliterans organizing pneumonia (BOOP) and pulmonary fibrosis], some fatal, with no identified infectious etiology have occurred in patients receiving immunosuppressive regimens including Rapamune. In some cases, the interstitial lung disease has resolved upon discontinuation or dose reduction of Rapamune. The risk may be increased as the sirolimus trough concentration increases. Occurrence of pulmonary hemorrhage coincident with sirolimus administration has been reported in selected patients. Symptomatic improvement or resolution were seen after withdrawal of sirolimus. Pleural effusion reports have been common. Rare reports of alveolar proteinosis have been received.

**Skin and Appendages:** Abnormal healing following transplant surgery has been reported, including fascial dehiscence, incisional hernia and anastomotic disruption (e.g., wound, vascular, airway, ureteral, biliary).

**Urogenital System:** Azoospermia reports have been uncommon. Azoospermia reported with the use of Rapamune has been reversible upon discontinuation of Rapamune in most cases (see TOXICOLOGY, Carcinogenicity, Mutagenesis, and Impairment of Fertility). Focal segmental glomerulosclerosis (frequency unknown) has been reported.

## DRUG INTERACTIONS

### Serious Drug Interactions

- Co-administration of Rapamune with strong inhibitors of CYP3A4 (such as ketoconazole, voriconazole, itraconazole, telithromycin, or clarithromycin) or inducers of CYP3A4 (such as rifampin or rifabutin) is not recommended.

## Overview

Sirolimus is extensively metabolized by the CYP3A4 isozyme in the gut wall and liver and undergoes counter-transport from enterocytes of the small intestine by the P-glycoprotein drug-efflux pump. Therefore, absorption and the subsequent elimination of systemically absorbed sirolimus may be influenced by drugs that affect these proteins. A summary of the potential effects of these concomitantly administered drugs on the pharmacokinetics of sirolimus is given in Table 6.

**Table -6: RATIOS OF SIROLIMUS PHARMACOKINETIC PARAMETERS AFTER CO-ADMINISTRATION WITH POTENTIALLY INTERACTING DRUGS**

		Ratio of Sirolimus Pharmacokinetic Parameters <sup>a,b</sup>				
Population	Interacting Drug	t <sub>max</sub>	C <sub>max</sub>	t <sub>1/2</sub>	AUC	CL/F/W
<b>Healthy subjects</b>	Acyclovir	0.95	:	:	:	:
	Cyclosporine microemulsion (simultaneous dosing) <sup>d</sup>	1.92	2.16	:	3.3	0.3
	Cyclosporine microemulsion (4 h dosing separation) <sup>d</sup>	1.58	1.37	1.1	1.8	0.56
	Cyclosporine microemulsion (simultaneous dosing) <sup>e</sup>	0.7	6.12	0.93	2.48	0.4
	Cyclosporine microemulsion (4 h dosing separation) <sup>e</sup>	0.67	1.33	0.9	1.33	0.75
	Cyclosporine microemulsion (simultaneous dosing) <sup>f</sup>	1.47	2.17	0.87	2.8	0.35
	Cyclosporine microemulsion (2 h after sirolimus dose) <sup>f</sup>	0.95	0.98	0.97	0.99	1.01
	Cyclosporine microemulsion (2 h before sirolimus dose) <sup>f</sup>	1.47	2.26	0.87	2.4	0.42
	Digoxin	1.03	:	:	:	:
	Diltiazem	1.29	1.43	0.85	1.6	0.38
	Glyburide	:	:	:	:	:
	Ketoconazole	1.38	4.42	:	10.9	0.085
	Nifedipine	:	:	:	:	:
	Norgestrel/ethinyl estradiol	-	-	0.86	1.08	:
	Rifampicin	:	0.29	:	0.18	5.53
	<b>Renal post-transplant Psoriasis</b>	Sulfamethoxazole/trimethoprim	:	:	-	:
Cyclosporine liquid (simultaneous dosing)		-	-	-	1.75 <sup>c</sup>	-

a: Ratio = (sirolimus + drug): (sirolimus alone).

b: : = no statistically significant change.

c: Ratio of average sirolimus trough concentrations.

d: 10 mg dose of sirolimus oral solution; 300 mg dose of cyclosporine microemulsion.

e: 10 mg dose of sirolimus tablet; 300 mg dose of cyclosporine microemulsion.

f: 5 mg dose of sirolimus oral solution given simultaneously, 2 hours before or 2 hours after 300 mg dose of cyclosporine microemulsion.

Inhibitors of CYP3A4 and P-glycoprotein may increase sirolimus levels. Inducers of CYP3A4 and P-glycoprotein may decrease sirolimus levels. In patients in whom strong inhibitors or

inducers of CYP3A4 and P-glycoprotein are indicated, alternative therapeutic agents with less potential for inhibition or induction of CYP3A4 and P-glycoprotein should be considered.

Care should be exercised when drugs or other substances that are nephrotoxic (eg, ganciclovir) or that are metabolized by CYP3A4 are administered concomitantly with Rapamune.

**Rhabdomyolysis HMG-CoA reductase inhibitors and/or fibrates:** In clinical trials, the concomitant administration of Rapamune and HMG-CoA reductase inhibitors and/or fibrates was well tolerated. During Rapamune therapy with or without cyclosporine, patients should be monitored for elevated lipids and patients administered an HMG-CoA reductase inhibitor and/or fibrate should be monitored for the possible development of rhabdomyolysis and other adverse effects as described in the respective labeling for these agents. (See WARNINGS AND PRECAUTIONS – Special Populations - Musculoskeletal.)

**Calcineurin Inhibitors:** Calcineurin inhibitor-induced hemolytic uremic syndrome/thrombotic thrombocytopenic purpura/thrombotic microangiopathy (HUS/TTP/TMA) has been reported in patients receiving sirolimus with a calcineurin inhibitor.

**Vaccination:** Immunosuppressants may affect response to vaccination. Therefore, during treatment with Rapamune, vaccination may be less effective. The use of live vaccines should be avoided; live vaccines may include, but are not limited to measles, mumps, rubella, oral polio, BCG, yellow fever, varicella, and TY21a typhoid.

### **Drug-Drug Interactions**

*The drugs listed in Table 7 are based on either drug interaction case reports or studies, or potential interactions due to the expected magnitude and seriousness of the interaction (i.e., those identified as contraindicated).*

**Table -7: ESTABLISHED OR POTENTIAL DRUG-DRUG INTERACTIONS**

<b>Drug Name</b>	<b>Ref</b>	<b>Effect</b>	<b>Clinical comment</b>
Cyclosporine (microemulsion)	CT	Multiple dose, staggered administration of Rapamune and cyclosporine ↓ cyclosporine oral dose clearance.	Based on dosing design of Phase III trials, it is recommended that Rapamune be administered 4 hours after cyclosporine microemulsion (Neoral <sup>®</sup> ); slightly lower doses of cyclosporine needed to meet target cyclosporine concentrations.

**Table -7: ESTABLISHED OR POTENTIAL DRUG-DRUG INTERACTIONS**

<b>Drug Name</b>	<b>Ref</b>	<b>Effect</b>	<b>Clinical comment</b>
Diltiazem	CT	Co-administration of 10 mg Rapamune oral solution and diltiazem (120 mg) ↑ sirolimus C <sub>max</sub> , T <sub>max</sub> , AUC 1.4-, 1.3-, and 1.6-fold, respectively. Sirolimus did not affect the pharmacokinetics of either diltiazem or its metabolites desacetyldiltiazem and desmethyldiltiazem.	Sirolimus levels should be monitored and a dose adjustment of Rapamune may be necessary.
Erythromycin	CT	Multiple dose co-administration ↑ whole blood sirolimus C <sub>max</sub> , T <sub>max</sub> , and AUC 4.4-, 1.4-, and 4.2-fold, respectively, and ↑ C <sub>max</sub> , T <sub>max</sub> , and AUC of plasma erythromycin base 1.6-, 1.3-, and 1.7-fold, respectively.	Sirolimus levels should be monitored and appropriate dose reductions of both medications should be considered.
Ketoconazole	CT	Multiple-dose co-administration of sirolimus ↑ sirolimus C <sub>max</sub> , T <sub>max</sub> , and AUC 4.4-, 1.4-, and 10.9-fold, respectively.	Co-administration of Rapamune and ketoconazole is not recommended. Ketoconazole significantly affected the rate and extent of absorption and sirolimus exposure.
Rifampicin	CT	Pretreatment with multiple doses of rifampicin, 600 mg daily for 14 days, greatly ↓ sirolimus exposure following a single 10 mg dose of Rapamune oral solution.	Co-administration of Rapamune and rifampicin is not recommended.
Verapamil	CT	Multiple-dose co-administration of verapamil and Rapamune oral solution ↑ sirolimus C <sub>max</sub> , T <sub>max</sub> , and AUC 2.3-, 1.1-, and 2.2-fold, respectively, and plasma S-(-) verapamil C <sub>max</sub> and AUC were both increased 1.5-fold, and t <sub>max</sub> ↓ 24%.	Sirolimus levels should be monitored and appropriate dose reductions of both medications should be considered.

Legend: C = Case Study; CT = Clinical Trial; T = Theoretical

### Other Inhibitors and Inducers of CYP3A4:

Care should be exercised and monitoring of sirolimus blood levels is recommended when drugs and other substances that are substrates and/or inhibitors or inducers of CYP3A4 are administered concomitantly with Rapamune. Other substances, aside from those mentioned above, that inhibit CYP3A4 include but are not limited to:

- Calcium channel blockers: nicardipine.
- Antifungal agents: clotrimazole, fluconazole.
- Antibiotics: troleandomycin.
- Gastrointestinal prokinetic agents: cisapride, metoclopramide.

- Other drugs: bromocriptine, cimetidine, cyclosporine, danazol, protease inhibitors (eg, for HIV that include drugs such as ritonavir, indinavir, and hepatitis C drugs such as boceprevir, and telaprevir).
- Grapefruit juice.

Other substances, aside from those mentioned above, that induce CYP3A4 include but are not limited to:

- Anticonvulsants: carbamazepine, phenobarbital, phenytoin.
- Antibiotics: rifapentine.

This list is not all-inclusive.

There were no clinically significant drug-drug interactions between sirolimus and acyclovir, atorvastatin, digoxin, glyburide, nifedipine, norgestrel 0.3 mg/ethinyl estradiol 0.03 mg, methylprednisolone, sulfamethoxazole/trimethoprim or tacrolimus. Therefore, they may be coadministered without dose adjustments.

Drug interaction studies have not been conducted with other drugs that may be commonly administered to renal transplant patients.

### **Drug-Food Interactions**

The bioavailability of sirolimus is affected by concomitant food intake after administration of Rapamune oral solution or tablet. Rapamune should be taken consistently, either with or without food to minimize blood level variability. Grapefruit juice reduces CYP3A4-mediated drug metabolism and potentially enhances P-glycoprotein-mediated drug counter-transport from enterocytes of the small intestine. Grapefruit juice must not be taken with Rapamune tablets or oral solution or be used for oral solution dilution.

### **Drug-Herb Interactions**

St. John's Wort (*Hypericum perforatum*) induces CYP3A4 and P-glycoprotein. Since sirolimus is a substrate for both cytochrome CYP3A4 and P-glycoprotein, there is the potential that the use of St. John's Wort in patients receiving Rapamune could result in reduced whole blood sirolimus concentrations.

### **Drug-Laboratory Interactions**

No studies have been conducted on the interactions of sirolimus in commonly employed clinical laboratory tests.

### **Drug-Lifestyle Interactions**

No studies have been conducted on the interactions of sirolimus with lifestyle.

## **DOSAGE AND ADMINISTRATION**

### **Dosing Considerations**

- *In patients at low to moderate immunological risk*, it is recommended that Rapamune should be used initially in a regimen with cyclosporine and corticosteroids. Cyclosporine withdrawal is recommended 2 to 4 months after transplantation in patients at low to moderate immunologic risk.
- *In patients at high immunologic risk*, it is recommended that Rapamune be used in combination with cyclosporine and corticosteroids for the first year following transplantation (See DOSAGE AND ADMINISTRATION and CLINICAL TRIALS).
- To minimize the variability of exposure to Rapamune, this drug should be taken once daily, preferably at the same time of day, and consistently with or without food.
- Cyclosporine microemulsion enhances absorption of Rapamune (See DRUG INTERACTIONS). It is recommended that sirolimus be taken 4 hours after cyclosporine microemulsion administration.
- A daily dose of 2 mg Rapamune Tablets has been demonstrated to be clinically equivalent to 2 mg Rapamune Oral Solution. However, it is not known if higher doses of Rapamune tablets and oral solution are clinically equivalent on a mg-to-mg basis. (See ACTION AND CLINICAL PHARMACOLOGY).
- It is recommended that a sirolimus trough concentration be taken 1 or 2 weeks after switching Rapamune formulations or tablet strengths or altering the total daily dose to confirm that the trough concentration is within the recommended target range (see

WARNINGS AND PRECAUTIONS – Monitoring and Laboratory Tests – Blood Concentration Monitoring).

- Blood sirolimus trough levels should be monitored:
  - In patients receiving concentration-controlled Rapamune.
  - In pediatric patients
  - In patients with hepatic impairment.
  - During concurrent administration of inhibitors and inducers of CYP3A4 and P-glycoprotein.
  - If the cyclosporine dose is markedly reduced, or if cyclosporine is discontinued.
- The Rapamune dosage need not be adjusted because of **impaired renal function** (See ACTION AND CLINICAL PHARMACOLOGY - Special Populations and Conditions - Renal Insufficiency).
- It is recommended that the maintenance dose of Rapamune be reduced by approximately one third to one-half in patients with **hepatic impairment**. It is not necessary to modify the Rapamune loading dose. (See ACTION AND CLINICAL PHARMACOLOGY - Special Populations and Conditions - Hepatic Insufficiency). In patients with hepatic impairment, it is recommended that sirolimus whole blood trough levels be monitored.
- Based on the finding that blood clearance decreases linearly with age, consideration should be given to reducing the Rapamune dose in patients 65 years of age and over. (See Pharmacokinetics, Special populations, Geriatrics).
- The safety and efficacy of Rapamune in pediatric patients below the age of 13 years have not been established. The initial loading dose should be 3 mg/m<sup>2</sup> in patients ≥ 13 years who weigh less than 40 kg. The maintenance dose should be adjusted, based on body surface area, to 1 mg/m<sup>2</sup>/day. It is recommended that sirolimus whole blood trough levels be monitored.
- The bioavailability of sirolimus (oral solution or tablet) is altered by concomitant food intake after administration. Rapamune should be taken consistently, either with or without food to minimize blood level variability.

- Bioavailability has not been determined for tablets after they have been crushed, chewed, or split and therefore this cannot be recommended. Patients unable to take the tablets should be prescribed the oral solution and instructed in its use.

## **Recommended Dose and Dosage Adjustment**

### **Patients at Low to Moderate Immunological Risk**

**Rapamune and Cyclosporine Combination Therapy:** The initial dose of Rapamune should be administered as soon as possible after transplantation. For *de novo* transplant recipients, a loading dose of Rapamune corresponding to 3 times the maintenance dose should be given. For most patients, the maintenance dose is 2 mg/day, with a loading dose of 6 mg.

Although a maintenance dose of 5 mg/day, with a loading dose of 15 mg, was used in clinical trials of the oral solution and was shown to be safe and effective, no efficacy advantage over the 2 mg dose could be established for renal transplant patients. Patients receiving 2 mg of Rapamune oral solution per day demonstrated an overall better safety profile than did patients receiving 5 mg of Rapamune oral solution per day.

It is recommended that Rapamune oral solution and tablets be used initially in a regimen with cyclosporine and corticosteroids. Cyclosporine should be withdrawn 2 to 4 months after renal transplantation in patients at low to moderate immunologic risk, and the Rapamune dose should be increased to reach recommended blood concentrations (See Rapamune Maintenance Regimen) Cyclosporine withdrawal has not been studied in patients with Banff 93 grade III acute rejection or vascular rejection prior to cyclosporine withdrawal, those who are dialysis-dependent, or with serum creatinine > 4.5 mg/dL, Black patients, re-transplants, multi-organ transplants, or patients with high-panel reactive antibodies (See CLINICAL TRIALS).

It is recommended that Rapamune be taken 4 hours after cyclosporine microemulsion [(cyclosporine, USP) MODIFIED] administration.

### **Rapamune Maintenance Regimen (RMR, Rapamune following cyclosporine withdrawal):**

Initially, patients considered for cyclosporine withdrawal should be receiving Rapamune and cyclosporine combination therapy. At 2 to 4 months following transplantation, cyclosporine should be progressively discontinued over 4 to 8 weeks and the Rapamune dose should be adjusted to obtain whole blood trough concentrations within the range of 16 to 24 ng/mL

(chromatographic method) for the first year following transplantation. Thereafter, the target sirolimus concentrations should be 12 to 20 ng/mL (chromatographic method). The actual observations at year 1 and 5 were close to these ranges (See WARNINGS AND PRECAUTIONS – Monitoring and Laboratory Tests – Blood Concentration Monitoring).

### **Patients at High Immunological Risk**

**Rapamune Combination Therapy:** It is recommended that Rapamune be used in combination with cyclosporine and corticosteroids for the first year following transplantation in patients at high immunologic risk (defined as Black transplant recipients and/or repeat renal transplant recipients who lost a previous allograft for immunologic reason and/or patients with high-panel reactive antibodies [PRA; peak PRA level > 80%]) (See CLINICAL TRIALS).

The safety and efficacy of these combinations in high-risk patients have not been studied beyond one year. Therefore, after the first year following transplantation, any adjustments to the immunosuppressive regimen should be considered on the basis of the clinical status of the patient.

For patients receiving Rapamune with cyclosporine, Rapamune therapy should be initiated with a loading dose of up to 15 mg on day 1 post-transplantation. Beginning on day 2, an initial maintenance dose of 5 mg/day should be given. A trough level should be obtained between days 5 and 7, and the daily dose of Rapamune should thereafter be adjusted to achieve whole blood trough sirolimus concentrations of 10-15 ng/mL.

The starting dose of cyclosporine should be up to 7 mg/kg/day in divided doses, and the dose should subsequently be adjusted to achieve whole blood trough concentrations of 200-300 ng/mL through week 2, 150-200 ng/mL from week 2 to week 26, and 100-150 ng/mL from week 26 to week 52. Prednisone should be administered at a minimum of 5 mg/day.

Antibody induction therapy may be used (See CLINICAL TRIALS).

### **Rapamune Dosage Adjustment**

Therapeutic drug monitoring should not be the sole basis for adjusting Rapamune therapy. Careful attention should be made to clinical signs/symptoms, tissue biopsies, and laboratory parameters (See DRUG INTERACTIONS).

Cyclosporine inhibits the metabolism and transport of sirolimus, and consequently, whole blood sirolimus concentrations will decrease when cyclosporine is discontinued unless the Rapamune dose is increased. The Rapamune dose will need to be approximately 4-fold higher to account for both the absence of the pharmacokinetic interaction with cyclosporine (approximately 2-fold increase) and the augmented immunosuppressive requirement in the absence of cyclosporine (approximately 2-fold increase).

Sirolimus has a long half-life; therefore frequent Rapamune dose adjustments based on non-steady-state sirolimus concentrations can lead to overdosing or underdosing. Once the Rapamune maintenance dose is adjusted, patients should be retained on the new maintenance dose for at least 7 to 14 days before further dosage adjustment with trough concentration monitoring.

In most patients dose adjustments can be based on simple proportion:

$$\text{New Rapamune dose} = \text{Current Dose} \times (\text{Target Concentration} / \text{Current Concentration})$$

A loading dose should be considered in addition to a new maintenance dose when it is necessary to considerably increase sirolimus trough concentrations:

$$\text{Rapamune Loading Dose} = 3 \times (\text{New Maintenance Dose} - \text{Current Maintenance Dose})$$

The maximum Rapamune dose administered on any day should not exceed 40 mg. If an estimated daily dose would exceed 40 mg due to the addition of a loading dose, the loading dose should be administered over 2 days. Sirolimus trough concentrations should be monitored at least 3 to 4 days after a loading dose(s).

### **Missed Dose**

A missed dose should be taken as soon as remembered, but not within 4 hours of the next dose of cyclosporine. Medicines can then be taken as usual. If a dose is missed completely, a double dose should not be taken to make up for a forgotten dose.

## **Administration**

### **Instructions for Dilution and Administration of Rapamune Oral Solution:**

The amber oral dose syringe should be used to withdraw the prescribed amount of Rapamune from the bottle. Empty the correct amount of Rapamune from the syringe into a glass or plastic container holding at least two (2) ounces (¼ cup; 60 mL) of water or orange juice. No other liquids, including grapefruit juice, should be used for dilution. Stir vigorously and drink at once. Rinse the container with an additional volume (minimum of four [4] ounces; ½ cup; 120 mL) of water or orange juice, stir vigorously, and drink at once.

Rapamune oral solution contains polysorbate-80, which is known to increase the rate of di-(2-ethylhexyl)phthalate (DEHP) extraction from polyvinyl chloride (PVC). This should be considered during the preparation and administration of Rapamune oral solution. It is important that the recommendations in this section be followed closely.

### **Instructions for Rapamune Tablets:**

Rapamune tablets should be taken with orange juice or water only. Rapamune tablets should not be taken with grapefruit juice.

## **OVERDOSAGE**

For management of a suspected drug overdose, contact your Regional Poison Control Centre.
---

There is limited experience with overdose. In general, the adverse effects of overdose are consistent with those listed in the ADVERSE REACTIONS section. During clinical trials, there were two accidental Rapamune (sirolimus oral solution) ingestions, of 120 mg and 150 mg. One patient, receiving 150 mg, experienced an episode of transient atrial fibrillation. The other patient experienced no adverse effects. General supportive measures should be followed in all cases of overdose. Based on the poor aqueous solubility and high erythrocyte and plasma protein binding of Rapamune, it is anticipated that Rapamune is not dialyzable to any significant extent.

In mice and rats, the acute oral LD<sub>50</sub> was greater than 800 mg/kg.

## **ACTION AND CLINICAL PHARMACOLOGY**

### **Mechanism of Action**

Rapamune is a potent immunosuppressive agent. Sirolimus is a macrocyclic lactone produced by *Streptomyces hygroscopicus*. Sirolimus inhibits T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (Interleukin [IL]-2, IL-4, IL-7, and IL-15) stimulation by a mechanism that is distinct from that of other immunosuppressants. Sirolimus also inhibits antibody production. In cells, sirolimus binds to the immunophilin, FK Binding Protein-12 (FKBP-12), to generate an immunosuppressive complex. Unlike cyclosporine and tacrolimus, the sirolimus:FKBP-12 complex has no effect on calcineurin activity. Rather, this complex binds to and inhibits the activation of a specific cell cycle regulatory protein called the mammalian Target Of Rapamycin (mTOR). mTOR is a key regulatory kinase and its inhibition by sirolimus suppresses cytokine-driven T-cell proliferation, inhibiting the progression from the G1 to the S phase of the cell cycle.

### **Pharmacodynamics**

In *in vitro* studies, sirolimus inhibits proliferation of T lymphocytes, B lymphocytes, and vascular and bronchial smooth muscle cells induced by cytokines and growth factors. Because sirolimus affects lymphocyte activation by a different mechanism, activation stimuli that resist inhibition by cyclosporine and tacrolimus have been shown to be sensitive to sirolimus. Sirolimus also affects B cell activation and antibody production. These effects contribute to the immunosuppressive properties of sirolimus.

Sirolimus prolongs allograft survival in animal models of transplantation, ranging from rodents to primates, both for solid organ and for cellular allografts. In mice, sirolimus prolongs the survival of heart, skin and islet allografts. Sirolimus prevents acute rejection of heart, kidney, small bowel, and pancreatico-duodenal grafts in rats and induces long-term tolerance. In rats, sirolimus reverses ongoing acute rejection of heart, kidney, and pancreas allografts, and suppresses accelerated heart allograft rejection in presensitized hosts. Sirolimus also prevents acute rejection of kidney allografts in dogs, pigs and baboons, as well as pancreatic islet cell rejection in dogs. Although in animals, sirolimus improves allograft survival as a single agent, it is synergistic with cyclosporine and is effective in combination with tacrolimus.

In animal models of autoimmune disease, sirolimus suppresses immune-mediated events associated with systemic lupus erythematosus, collagen-induced arthritis, autoimmune type I

diabetes, autoimmune myocarditis, experimental allergic encephalomyelitis, graft versus host disease, and autoimmune uveoretinitis.

In rodents and primates, sirolimus mitigates the progression of chronic rejection by reducing the vascular intimal proliferation that is characteristic of chronic vascular rejection. In a pig model of coronary restenosis after angioplasty, sirolimus reduces the vascular proliferative response to mechanical vascular injury.

Animal studies have shown that sirolimus-mediated immunosuppression is reversible.

In an open-label, randomized, comparative, multicenter study where renal transplant patients were either converted from tacrolimus to sirolimus 3 to 5 months post-transplant or remained on tacrolimus, there was no significant difference in renal function at 2 years. There were more adverse events (99.2% versus 91.1%,  $p=0.002$ ) and more discontinuations from the treatment due to adverse events (26.7% versus 4.1%,  $p<0.001$ ) in the group converted to sirolimus compared to the tacrolimus group. The incidence of biopsy confirmed acute rejection was higher ( $p=0.020$ ) for patients in the sirolimus group (11, 8.4%) compared to the tacrolimus group (2, 1.6%) through 2 years; most rejections were mild in severity (8 of 9 [89%] T-cell BCAR, 2 of 4 [50%] antibody mediated BCAR) in the sirolimus group. Patients who had both antibody-mediated rejection and T-cell-mediated rejection on the same biopsy were counted once for each category. More patients converted to sirolimus developed new onset diabetes mellitus defined as 30 days or longer of continuous or at least 25 days non-stop (without gap) use of any diabetic treatment after randomization, a fasting glucose  $\geq 126$  mg/dL or a non-fasting glucose  $\geq 200$  mg/dL after randomization (18.3% versus 5.6%,  $p=0.025$ ). A lower incidence of squamous cell carcinoma of the skin was observed in the sirolimus group (0% versus 4.9%).

### **Pharmacokinetics**

Sirolimus pharmacokinetic activity has been determined following oral administration in healthy subjects, pediatric dialysis patients, hepatically impaired patients and renal transplant patients. Sirolimus is rapidly absorbed and undergoes extensive metabolism to seven major metabolites that do not contribute significantly to the pharmacological effect.

#### **Absorption:**

Following administration of Rapamune oral solution, sirolimus is rapidly absorbed, with a time to peak concentration ( $t_{max}$ ) of 1 hour in healthy subjects and 2-3 hours in renal transplant

recipients. Following administration of Rapamune tablet, sirolimus  $t_{\max}$  was approximately 3 hours after single doses in healthy volunteers and multiple doses in renal transplant patients. The systemic availability of sirolimus is approximately 14% after the administration of Rapamune Oral Solution. The mean bioavailability of sirolimus after administration of the Rapamune tablet is about 22% higher relative to the oral solution. Sirolimus tablets are not bioequivalent to the oral solution; however, clinical equivalence has been demonstrated at the 2 mg dose level over a 12-month period in renal allograft recipients, where clinical equivalence was measured as the rate of occurrence of the composite endpoint of first biopsy-proven acute rejection, graft loss, or death in the first 3 months after transplantation. (See CLINICAL TRIALS – Rapamune Tablets and DOSAGE AND ADMINISTRATION). Sirolimus concentrations are dose proportional between 3 and 12 mg/m<sup>2</sup> following the administration of Rapamune oral solution to stable renal transplant patients, and between 5 and 40 mg after administration of Rapamune tablets in healthy volunteers. Upon repeated administration to stable renal transplant patients, the average blood concentration of sirolimus was increased approximately 3-fold.

Bioequivalence testing of the various sirolimus tablet strengths in healthy volunteers (n = 22) showed that 10 mg doses of the 1 mg, 2 mg, and 5 mg tablets were equivalent with respect to  $C_{\max}$ ,  $AUC_{0-72h}$  and  $AUC_{0-\infty}$  (see CLINICAL TRIALS – Comparative Bioavailability Studies).

Food effects: In 22 healthy volunteers receiving Rapamune oral solution, a high fat breakfast (861.8 kcal, 54.9% kcal from fat) altered the bioavailability characteristics of sirolimus. Compared with fasting, a 34% decrease in the peak blood sirolimus concentration ( $C_{\max}$ ), a 3.5-fold increase in the time to peak concentration ( $t_{\max}$ ), and a 35% increase in total exposure (AUC) was observed. The change in bioavailability is not clinically important. After administration of Rapamune tablets and a high-fat meal in 24 healthy volunteers,  $C_{\max}$ ,  $t_{\max}$ , and AUC showed increases of 65%, 32%, and 23%, respectively. Thus, a high-fat meal produced differences in the two formulations with respect to rate of absorption but not in extent of absorption. Evidence from a large randomized multicentre controlled trial comparing Rapamune oral solution to tablets, supports that the differences in absorption rate do not affect the efficacy of the drug.

To minimize variability, both Rapamune oral solution and tablets should be taken consistently with or without food (See DOSAGE AND ADMINISTRATION). Bioequivalence testing based on AUC and  $C_{\max}$  showed that Rapamune administered with orange juice is equivalent to administration with water. Therefore, orange juice and water may be used interchangeably as administration liquids for Rapamune (See DOSAGE AND ADMINISTRATION). Grapefruit

juice reduces CYP3A4-mediated drug metabolism and potentially enhances P-glycoprotein-mediated drug counter-transport from enterocytes of the small intestine. Grapefruit juice must not be taken with Rapamune tablets or oral solution or be used for oral solution dilution.

### **Distribution:**

The mean ( $\pm$  SD) blood-to-plasma ratio of sirolimus was  $36 \pm 17.9$  in stable renal allograft recipients after administration of Rapamune oral solution, indicating that sirolimus is extensively partitioned into formed blood elements. The mean volume of distribution ( $V_{ss}/F$ ) of sirolimus by Rapamune oral solution is  $12 \pm 7.52$  L/kg. Sirolimus is extensively bound (approximately 92%) to human plasma proteins. In man, the binding of sirolimus was shown mainly to be associated with serum albumin (97%),  $\alpha_1$ -acid glycoprotein, and lipoproteins.

### **Metabolism:**

Sirolimus is a substrate for both cytochrome P450 IIIA4 (CYP3A4) and P-glycoprotein. Sirolimus is extensively metabolized by O-demethylation and/or hydroxylation. Seven major metabolites, including hydroxy, demethyl, and hydroxydemethyl, are identifiable in whole blood. Some of these metabolites are also detectable in plasma, fecal, and urine samples. The glucuronide and sulfate conjugates are not present in any of the biologic matrices. The combined demethyl and hydroxy metabolites show  $\leq 30\%$  of the *in vitro* immunosuppressive activity of sirolimus.

### **Excretion:**

After a single dose of [ $^{14}\text{C}$ ] sirolimus by oral solution in healthy volunteers, the majority (91%) of radioactivity was recovered from the feces, and only a minor amount (2.2%) was excreted in urine.

The mean  $\pm$  SD terminal elimination half-life ( $t_{1/2}$ ) of sirolimus after multiple dosing by Rapamune oral solution in stable renal transplant patients was estimated to be  $62 \pm 16$  hours.

## **Pharmacokinetics in renal transplant patients**

### **Rapamune and cyclosporine combination therapy:**

**Rapamune Oral Solution:** Mean ( $\pm$  SD) pharmacokinetic parameters for Rapamune oral solution given daily in combination with cyclosporine and corticosteroids in renal transplant patients were determined at months 1, 3, and 6 after transplantation (Study 1; See CLINICAL TRIALS). There were no significant differences in any of these parameters with respect to treatment group or month. Whole blood sirolimus trough concentrations (mean  $\pm$  SD) for the 2

mg/day and 5 mg/day dose groups were  $8.6 \pm 4.0$  ng/mL (n=226) and  $17.3 \pm 7.4$  ng/mL (n=219), respectively. Whole blood trough sirolimus concentrations were significantly correlated ( $r^2=0.95$ ) with  $AUC_{9,ss}$ . The table below provides a summary of these sirolimus pharmacokinetic parameters.

**Table -8: SIROLIMUS PHARMACOKINETIC PARAMETERS (MEAN  $\pm$  SD) IN RENAL TRANSPLANT PATIENTS (MULTIPLE DOSE ORAL SOLUTION) <sup>a, b</sup>**

n	Dose	$C_{max,ss}$ <sup>c</sup> (ng/mL)	$t_{max,ss}$ (h)	$AUC_{9,ss}$ <sup>c</sup> (ng•h/mL)	CL/F <sup>d</sup> (mL/h/kg)
19	2 mg	$12.2 \pm 6.2$	$3.01 \pm 2.40$	$158 \pm 70$	$182 \pm 72$
23	5 mg	$37.4 \pm 21$	$1.84 \pm 1.30$	$396 \pm 193$	$221 \pm 143$

a: Sirolimus administered four hours after cyclosporine microemulsion.

b: As measured by the Liquid Chromatographic/Tandem Mass Spectrometric Method (LC/MS/MS).

c: These parameters are dose normalized for the statistical comparison.

d: CL/F= oral dose clearance.

**Rapamune Tablets:** Pharmacokinetic parameters for Rapamune tablets administered daily in combination with cyclosporine and corticosteroids in renal transplant patients are summarized below based on data collected at months 1 and 3 after transplantation (Study 3; See CLINICAL TRIALS).

**Table -9: SIROLIMUS PHARMACOKINETIC PARAMETERS (MEAN  $\pm$  SD) IN RENAL TRANSPLANT PATIENTS (MULTIPLE DOSE TABLETS) <sup>a, b</sup>**

n	Dose (2 mg/day)	$C_{max,ss}$ <sup>c</sup> (ng/mL)	$t_{max,ss}$ (h)	$AUC_{9,ss}$ <sup>c</sup> (ng•h/mL)	CL/F <sup>d</sup> (mL/h/kg)
17	Oral solution	$14.4 \pm 5.3$	$2.12 \pm 0.84$	$194 \pm 78$	$173 \pm 50$
13	Tablets	$15.0 \pm 4.9$	$3.46 \pm 2.40$	$230 \pm 67$	$139 \pm 63$

a: Sirolimus administered four hours after cyclosporine microemulsion.

b: As measured by the Liquid Chromatographic/Tandem Mass Spectrometric Method (LC/MS/MS).

c: These parameters are dose normalized for the statistical comparison.

d: CL/F= oral dose clearance.

Whole blood sirolimus trough concentrations, (mean  $\pm$  SD), as measured by immunoassay, for 2 mg of oral solution and 2 mg of tablets over 6 months, were  $8.9 \pm 4.4$  ng/mL (n = 172) and  $9.5 \pm 3.9$  ng/mL (n = 179), respectively. Whole blood trough sirolimus concentrations, as measured by LC/MS/MS, were significantly correlated ( $r^2 = 0.85$ ) with  $AUC_{\tau,ss}$ . Mean whole blood sirolimus trough concentrations in patients receiving either Rapamune Oral Solution or Rapamune Tablets with a loading dose of three times the maintenance dose achieved steady-state concentrations within 24 hours after the start of dose administration.

**Use of Rapamune without concomitant cyclosporine administration:**

Average Rapamune doses and sirolimus whole blood trough concentrations for Rapamune tablets administered daily in combination with cyclosporine and following cyclosporine withdrawal, in combination with corticosteroids in renal transplant patients (Study 4; See CLINICAL TRIALS) are summarized in the table below.

**Table -10: AVERAGE RAPAMUNE DOSES AND SIROLIMUS TROUGH CONCENTRATIONS (MEAN ± SD) IN RENAL TRANSPLANT PATIENTS AFTER MULTIPLE DOSE TABLET ADMINISTRATION**

		Rapamune with Cyclosporine Therapy <sup>a</sup>	Rapamune Following Cyclosporine Withdrawal <sup>a</sup>
Rapamune Dose (mg/day)	Months 4 to 12	2.1 ± 0.7	8.2 ± 4.2
	Months 12 to 24	2.0 ± 0.8	6.4 ± 3.0
	Months 24 to 36	2.0 ± 0.8	5.0 ± 2.5
	Months 36 to 48	2.0 ± 0.8	4.8 ± 2.2
	Months 48 to 60	2.1 ± 1.0	4.4 ± 2.0
Sirolimus C <sub>min</sub> , (ng/mL) <sup>b</sup>	Months 4 to 12	10.7 ± 3.8	23.3 ± 5.0
	Months 12 to 24	11.2 ± 4.1	22.5 ± 4.8
	Months 24 to 36	11.4 ± 4.2	20.4 ± 5.4
	Months 36 to 48	10.8 ± 3.7	19.4 ± 5.6
	Months 48 to 60	10.7 ± 4.1	18.2 ± 5.3

a: 215 patients were randomized to each group.

b: Expressed by immunoassay and equivalence.

The time required for withdrawal of cyclosporine and concurrent increases in sirolimus trough concentrations to steady state was approximately 6 weeks. Larger Rapamune doses were required due to the absence of the inhibition of sirolimus metabolism and transport by cyclosporine and the need for higher target sirolimus concentrations during concentration-controlled administration of Rapamune following cyclosporine withdrawal.

**Pharmacokinetics in high-risk patients:**

Average Rapamune doses and sirolimus whole blood trough concentrations for tablets administered daily in combination with cyclosporine and corticosteroids in high-risk renal transplant patients (Clinical Trials) are summarized in the table below.

**Table -11: AVERAGE RAPAMUNE DOSES AND SIROLIMUS TROUGH CONCENTRATIONS (MEAN ± SD) IN HIGH-RISK RENAL TRANSPLANT PATIENTS AFTER MULTIPLE-DOSE TABLET ADMINISTRATION**

	Rapamune with Cyclosporine Therapy
Rapamune Dose (mg/day)	
Months 3 to 6 <sup>a</sup>	5.1 ± 2.4
Months 9 to 12 <sup>b</sup>	5.0 ± 2.3
Sirolimus C <sub>min</sub> (ng/mL) <sup>c</sup>	
Months 3 to 6	11.8 ± 4.2
Months 9 to 12	11.2 ± 3.8

a: n=109

b: n=127

c: Expressed by chromatography.

### **Special Populations and Conditions**

#### **Pediatrics (<13 years of age):**

Sirolimus pharmacokinetic data were collected in concentration-controlled trials of pediatric renal transplant patients who were also receiving cyclosporine and corticosteroids. The target ranges for trough concentrations were either 10-20 ng/mL for the 21 children receiving tablets, or 5-15 ng/mL for the one child receiving oral solution. The children aged 6-11 years (n=8) received mean ± SD doses of 1.75 ± 0.71 mg/day (0.064 ± 0.018 mg/kg, 1.65 ± 0.43 mg/m<sup>2</sup>). The children aged 12-18 years (n=14) received mean ± SD doses of 2.79 ± 1.25 mg/day (0.053 ± 0.0150 mg/kg, 1.86 ± 0.61 mg/m<sup>2</sup>). At the time of sirolimus blood sampling for pharmacokinetic evaluation, the majority (80%) of these pediatric patients received the sirolimus dose at 16 hours after the once daily cyclosporine dose.

**Table -12: SIROLIMUS PHARMACOKINETIC PARAMETERS (MEAN ± sd) IN PEDIATRIC RENAL TRANSPLANT PATIENTS (MULTIPLE DOSE CONCENTRATION CONTROL)<sup>a,b</sup>**

Age (y)	n	Body weight (kg)	C <sub>max,ss</sub> (ng/mL)	t <sub>max,ss</sub> (h)	C <sub>min,ss</sub> (ng/ml)	AUC <sub>τ,ss</sub> (ng•h/mL)	CL/F <sup>c</sup> (mL/h/kg)	CL/F <sup>c</sup> (L/h/m <sup>2</sup> )
6-11	8	27 ± 10	22.1 ± 8.9	5.88 ± 4.05	10.6 ± 4.3	356 ± 127	214 ± 129	5.4 ± 2.8
12-18	14	52 ± 15	34.5 ± 12.2	2.7 ± 1.5	14.7 ± 8.6	466 ± 236	136 ± 57	4.7 ± 1.9

a: Sirolimus co-administered with cyclosporine oral solution (MODIFIED) (e.g., Neoral Oral Solution) and/or cyclosporine capsules (MODIFIED) (e.g., Neoral Soft Gelatin Capsules).

b: As measured by Liquid Chromatographic/Tandem Mass Spectrometric Method (LC/MS/MS).

c: Oral-dose clearance adjusted by either body weight (kg) or body surface area (m<sup>2</sup>).

The table below summarizes pharmacokinetic data obtained in pediatric dialysis patients with chronically impaired renal function receiving Rapamune by oral solution.

**Table -13: SIROLIMUS PHARMACOKINETIC PARAMETERS (MEAN ± SD) IN PEDIATRIC PATIENTS WITH STABLE CHRONIC RENAL FAILURE MAINTAINED ON HEMODIALYSIS OR PERITONEAL DIALYSIS (1, 3, 9, 15 mg/m<sup>2</sup> SINGLE DOSE)**

Age Group (y)	n	t <sub>max</sub> (h)	t <sub>1/2</sub> (h)	CL/F/WT (mL/h/kg)
5-11	9	1.1 ± 0.5	71 ± 40	580 ± 450
12-18	11	0.79 ± 0.17	55 ± 18	450 ± 232

**Geriatrics (>65 years of age):**

A decrease in CL/F of approximately 13% per decade was observed in population analyses. Clinical studies of Rapamune did not include a sufficient number of patients > 65 years of age to determine whether they will respond differently than younger patients. After the administration of Rapamune oral solution, sirolimus trough concentration data in 35 renal transplant patients > 65 years of age were similar to those in the adult population (n=822) 18 to 65 years of age. Similar results were obtained after the administration of Rapamune tablets to 12 renal transplant patients > 65 years of age compared with adults (n=167) 18 to 65 years of age.

**Gender:**

The pharmacokinetic differences between males and females are relatively small. Rapamune oral dose clearance after Rapamune oral solution in males was 12% lower than that in females; male subjects had a significantly longer  $t_{1/2}$  than did female subjects (72.3 hours versus 61.3 hours). A similar trend in the effect of gender on sirolimus oral dose clearance and  $t_{1/2}$  was observed after the administration of Rapamune tablets. Dose adjustments based on gender are not recommended.

**Race:**

In large phase 3 trials (Studies 1 and 2) using Rapamune and cyclosporine (microemulsion, Neoral<sup>®</sup>), there were no significant differences in mean trough sirolimus concentrations or AUC over time between black (n=139) and non-black (n=724) patients during the first 6 months after transplantation at Rapamune doses of 2 mg/day and 5 mg/day by oral solution. Similarly, after administration of Rapamune Tablets (2 mg/day) in a phase 3 trial, mean sirolimus trough concentrations over 6 months were not significantly different among black (n=51) and non-black (n=128) patients. There is limited information on black patients from a Phase 3 trial (Study 4) using Rapamune with cyclosporine elimination. In a Phase 2 study of similar design to Study 4, mean dose-normalized sirolimus trough concentrations in the control group (sirolimus 2 mg/day + cyclosporine) over 12 months were significantly decreased by approximately 31% among black (n=17) patients compared with non-black (n=72) patients. The mean dose-normalized sirolimus trough concentrations over 12 months in the Rapamune (concentration-controlled 10-20 ng/mL) with cyclosporine elimination group were significantly decreased by approximately 15% among black (n=15) patients compared with non-black (n=76) patients.

**Hepatic Insufficiency:**

Shown below are the mean ( $\pm$  SD) pharmacokinetic parameters for sirolimus following the administration of sirolimus to subjects with hepatic impairment and healthy subjects. Rapamune (15 mg) was administered as a single dose by oral solution to subjects with normal hepatic function and to patients with Child-Pugh classification A (mild), B (moderate) or C (severe) hepatic impairment, in which hepatic impairment was primary and not related to an underlying systemic disease.

**Table -14: SIROLIMUS PHARMACOKINETIC PARAMETERS (MEAN ± SD) IN 18 HEALTHY SUBJECTS AND 18 PATIENTS WITH MILD TO MODERATE HEPATIC IMPAIRMENT (15 mg SINGLE DOSE)**

Population	C <sub>max,ss</sub> <sup>a</sup> (ng/mL)	t <sub>max</sub> (h)	AUC <sub>0-4</sub> (ng•h/mL)	CL/F (mL/h/kg)
Healthy subjects	78.2 ± 18.3	0.83 ± 0.17	970 ± 272	215 ± 76
Hepatic impairment	77.9 ± 23.1	0.84 ± 0.17	1567 ± 616	144 ± 62

a: As measured by LC/MS/MS.

**Table -15: WHOLE BLOOD SIROLIMUS PHARMACOKINETIC PARAMETERS (MEAN ± SD) IN 9 HEALTHY SUBJECTS AND 9 PATIENTS WITH SEVERE HEPATIC IMPAIRMENT (15 mg SINGLE DOSE)**

Group <sup>a</sup>	C <sub>max</sub> (ng/mL)	t <sub>max</sub> (h)	t <sub>1/2</sub> (h)	AUC (ng•h/mL)	CL/F (mL/h/kg)	V <sub>ss</sub> /F (L/kg)	MRT (h)
Healthy subjects	72.3 ± 16.6	0.78 ± 0.16	80.0 ± 5.4	838 ± 277	300 ± 66	34.5 ± 7.2	77.5 ± 6.4
Severe hepatic impairment	56.2 ± 23.1	0.82 ± 0.17	214.5 ± 68.9	2597 ± 1092	98.1 ± 43.8	29.1 ± 12.9	280 ± 99
----- p-Values from ANOVA -----							
	0.108	0.652	0.0001	0.0002	0.0001	0.286	0.0001

Abbreviations: ANOVA=analysis of variance; AUC=area under the concentration-time curve; CL/F=apparent oral dose clearance; C<sub>max</sub>=peak concentration; MRT=mean residence time; SD=standard deviation; t<sub>max</sub>=time peak concentration occurs; t<sub>1/2</sub>=terminal-phase elimination half-life; V<sub>ss</sub>/F= apparent oral-dose steady-state volume of distribution.

a. Sirolimus was administered by oral solution.

Compared with the values in the normal hepatic group, the hepatic impairment group had higher mean values for sirolimus AUC and t<sub>1/2</sub> and had lower mean values for sirolimus CL/F.

Sirolimus absorption was not altered by hepatic disease, as evidenced by no changes in C<sub>max</sub> and t<sub>max</sub> values. The initial maintenance dose of Rapamune should be reduced by approximately one third in patients with mild to moderate hepatic impairment and by approximately one half in patients with severe hepatic impairment. In patients with hepatic impairment, it is recommended that sirolimus whole blood trough levels be monitored. However, hepatic diseases with varying etiologies may show different effects.

### Renal Insufficiency:

There is minimal (2.2%) renal excretion of the drug or its metabolites. The pharmacokinetics of sirolimus are very similar in various populations with renal function ranging from normal to absent (dialysis patients).

## **STORAGE AND STABILITY**

Keep in a safe place out of the reach of children.

### **Rapamune Oral Solution:**

Rapamune Oral Solution bottles should be stored protected from exposure to light and refrigerated at 2°C to 8°C. Do not freeze. Rapamune is stable until the expiration date indicated on the container label. Once the bottle is opened, it should be kept in a refrigerator and the contents used within one month. If not refrigerated, the opened bottles may be stored at room temperature (15°C to 30°C) for up to 5 days.

An amber syringe and cap are provided for dosing and the product may be kept in the syringe for a maximum of 24 hours at room temperatures up to 30°C or refrigerated at 2°C to 8°C. The syringe should be discarded after one use. After dilution, the preparation should be used immediately.

Rapamune provided in bottles may develop a slight haze when refrigerated. If such a haze occurs allow the product to stand at room temperature and shake gently until the haze disappears. The presence of this haze does not affect the quality of the product.

### **Rapamune Tablets:**

Rapamune Tablets should be stored at 15°C to 30°C. Dispense in a light-resistant container. Protect from exposure to light. Rapamune is stable until the expiration date indicated on the container label.

## **SPECIAL HANDLING INSTRUCTIONS**

Since Rapamune is not absorbed through the skin, there are no special precautions. However, if direct contact with the skin or mucous membranes occurs, wash thoroughly with soap and water; rinse eyes with plain water.

## DOSAGE FORMS, COMPOSITION AND PACKAGING

Rapamune for oral administration is supplied as follows:

### Oral Solution:

Medicinal ingredients: Sirolimus 1mg/mL

Non-medicinal ingredients: Phosal 50 PG<sup>®</sup> (ascorbyl palmitate, ethanol, phosphatidylcholine, propylene glycol, soybean oil fatty acids and sunflower mono and diglycerides) and Polysorbate 80 NF.

### Tablets:

Medicinal ingredients: Sirolimus 1 mg, 2 mg or 5 mg

Non-medicinal ingredients: Calcium Sulfate Anhydrous NF, Carnauba Wax NF, Glyceryl Monooleate, Lactose Monohydrate NF, Magnesium Stearate NF, Microcrystalline Cellulose NF, Pharmaceutical Glaze NF, Polaxamer 188, Polyethylene Glycol 8000 Powdered NF, Polyethylene Glycol Type 20,000, Povidone USP, Vitamin E (*dl*-alpha tocopherol), Sucrose NF, Talc USP, Titanium Dioxide USP and Ink. In addition, the 2 mg tablet contains Brown #70 Iron Oxide NF and Yellow #10 Iron Oxide NF; the 5 mg tablet contains Brown #75 Iron Oxide NF, and Yellow #10 Iron Oxide NF.

## Availability of Dosage Forms

### **Oral Solution:**

Rapamune (sirolimus oral solution) is supplied at a concentration of 1 mg/mL in:

- Amber glass bottles of 60 mL

The bottles are supplied with an oral syringe adapter for fitting into the neck of the bottle and 30 disposable amber oral syringes and 30 caps for daily dosing.

### **Tablets:**

Rapamune (sirolimus tablets) is available as:

- a white, triangular-shaped tablet containing 1 mg sirolimus marked “RAPAMUNE 1 mg” on one side;
- a yellow-to-beige triangular-shaped tablet containing 2 mg sirolimus marked “RAPAMUNE 2 mg” on one side, and;
- a tan, triangular-shaped tablet containing 5 mg sirolimus marked “RAPAMUNE 5 mg” on one side.

The tablets are supplied in:

- Bottles of 100 tablets
- Unit dose cartons of 100 tablets (10 blister cards of 10 tablets each)

## PART II: SCIENTIFIC INFORMATION

### PHARMACEUTICAL INFORMATION


#### Drug Substance

Proper name: Sirolimus

Chemical name: (3*S*,6*R*,7*E*,9*R*,10*R*,12*R*,14*S*,15*E*,17*E*,19*E*,21*S*,23*S*,26*R*,27*R*,34*aS*)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34*a*-hexadecahydro-9,27-dihydroxy-3-[(1*R*)-2-[(1*S*,3*R*,4*R*)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3*H*-pyrido[2,1-*c*][1,4]oxaazacyclohentriacontine-1,5,11,28,29 (4*H*,6*H*,31*H*)-pentone

Molecular formula and molecular mass: C<sub>51</sub> H<sub>79</sub> NO<sub>13</sub> (914.2 g/mol)

Structural formula:



Physicochemical properties:

Physical Form: White to off-white powder

Solubility: Insoluble in water but freely soluble in benzyl alcohol, chloroform, acetone, and acetonitrile. Since the water solubility is so low and constant over the pH range (pH 1-10), the n-octanol/water log partition coefficient (PC) is also relatively constant (log PC=4.02)

Melting Point range: 179-181°C

## CLINICAL TRIALS

### Study Demographics and Trial Design

#### Rapamune and Cyclosporine Combination Therapy (Study 1, 2 and 3)

**Rapamune Oral Solution:** The safety and efficacy of Rapamune oral solution for the prevention of organ rejection following renal transplantation were assessed in two randomized, double-blind, multicentre, controlled trials. These studies compared two dose levels of Rapamune oral solution with azathioprine (Study 1) or placebo (Study 2) when administered in combination with cyclosporine and corticosteroids. In both studies, the use of antilymphocyte antibody induction therapy was prohibited.

**Rapamune Tablets:** The safety and efficacy of Rapamune oral solution and Rapamune tablets for the prevention of organ rejection following renal transplantation were compared in a randomized, multicentre, controlled trial (Study 3). This study compared a single dose level of Rapamune oral solution and Rapamune tablets when administered in combination with cyclosporine and corticosteroids. The use of antilymphocyte antibody induction therapy was prohibited.

#### Use of Rapamune without Concomitant Cyclosporine Administration (Study 4)

**Rapamune Maintenance Regimen (RMR):** The safety and efficacy of Rapamune as an immunosuppressive maintenance regimen were assessed following cyclosporine withdrawal at 3

months  $\pm$  2 weeks post renal transplantation in a randomized, multicentre, controlled trial (Study 4). This study compared patients who were administered Rapamune, cyclosporine, and corticosteroids continuously with patients who received the same standardized therapy for the first 3 months after transplantation (pre-randomization period) followed by the withdrawal of cyclosporine. Eligibility for randomization included no Banff Grade III (1993 criteria) acute rejection episode or vascular rejection in the 4 weeks before random assignment; serum creatinine  $\leq$  400  $\mu$ mol/L (4.5 mg/dL); and adequate renal function to support cyclosporine withdrawal (in the opinion of the investigator).

### Rapamune with Cyclosporine Administration (Study 5)

**High-Risk Patients Study:** Rapamune was studied in a one-year, randomized, open-label, controlled clinical trial in high risk patients who were defined as Black transplant recipients and/or repeat renal transplant recipients who lost a previous allograft for immunologic reason and/or patients with high-panel reactive antibodies (PRA; peak PRA level > 80%). Patients received concentration-controlled sirolimus and cyclosporine, and corticosteroids per local practice. Antibody induction was allowed per protocol as prospectively defined at each transplant center, and was used in 88.4% of patients.

The table below summarizes the demographics and trial design in controlled clinical trials that were conducted in renal transplant patients.

**Table -16: SUMMARY OF PATIENT DEMOGRAPHICS FOR CLINICAL TRIALS IN RENAL TRANSPLANTATION**

Study #	Trial design	Dosage, route of administration and duration	Study subjects (n)	Mean age (Range)	Gender (% male)
Study 1	Randomized, double blind, multicentre controlled trial	Treatment groups: Rapamune Oral Solution 2 mg/day Rapamune Oral Solution 5 mg/day Azathioprine 2-3 mg/kg/day All groups received CsA and corticosteroids. Duration 24 months.	284 274 161	45.8 (12-79)	65

**Table -16: SUMMARY OF PATIENT DEMOGRAPHICS FOR CLINICAL TRIALS IN RENAL TRANSPLANTATION**

Study #	Trial design	Dosage, route of administration and duration	Study subjects (n)	Mean age (Range)	Gender (% male)
Study 2	Randomized, double-blind, multicentre controlled trial	Treatment groups: Rapamune Oral Solution 2 mg/day Rapamune Oral Solution 5 mg/day Placebo All groups received CsA and corticosteroids. Duration 36 months.	227 219 130	45.5 (15-71)	67
Study 3	Randomized, placebo-controlled, multicentre controlled trial	Treatment groups: Rapamune Oral Solution 2 mg/day Rapamune Tablets 2 mg/day (2 x 1mg) Both groups received CsA and corticosteroids. Duration 12 months.	238 239	45.3 (16-74)	61
Study 4	Randomized, open label, 2-part, multicentre, controlled trial	<u>Part 1<sup>a</sup>:</u> Study Treatment: All patients - Rapamune Tablets 2 mg (target trough level > 5 ng/mL), CsA and corticosteroids.  <u>Part 2<sup>b</sup>:</u> Treatment Groups: Rapamune Tablets with Cyclosporine <sup>c</sup> Rapamune Tablets and Cyclosporine Withdrawal <sup>d</sup> Both groups received corticosteroids. Duration 60 months.	525  215 215	45.9 (16-73)	64
Study 5	Randomized, open label, concentration controlled, multicentre trial	Treatment Group <sup>e</sup> :  Rapamune, cyclosporine and coriticosteroids  12 month followup after transplant	224	44.4	56

a. Part 1: Pre-transplant screening/baseline to randomization at 3 months ± 2 weeks post-transplant.

b. Part 2: 3 months ± 2 weeks to 36 months post-transplant.

c. Sirolimus 2 mg/day (target trough level > 5 ng/mL), CsA and corticosteroids.

d. Sirolimus dose to target trough level 20-30 ng/mL for first 12 months; 15-25 ng/mL thereafter. At 3 months ± 2 weeks, CsA was eliminated over 4-6 weeks.

e. Evaluable population, subjects who were randomly assigned, underwent transplantation and received at least one dose of study medication. These were stratified by race, either black or non-black.

## Study Results

### Rapamune and Cyclosporine Combination Therapy (Studies 1, 2 and 3)

**Rapamune Oral Solution:** In both studies 1 and 2, the primary efficacy endpoint was the rate of efficacy failure in the first 6 months after transplantation. Efficacy failure was defined as the first occurrence of an acute rejection episode (confirmed by biopsy), graft loss, or death. The tables below summarize the results of the primary efficacy analyses from these trials. Rapamune oral solution, at doses of 2 mg/day and 5 mg/day, significantly reduced the incidence of the primary endpoint and the incidence of biopsy-proven acute rejection at 6 months following transplantation compared with both azathioprine and placebo.

**Table -17: INCIDENCE (%) OF THE PRIMARY ENDPOINT AT 6 MONTHS: STUDY 1<sup>a</sup>**

	Rapamune Oral Solution 2 mg/day (n = 284)	Rapamune Oral Solution 5 mg/day (n = 274)	Azathioprine 2-3 mg/kg/day (n = 161)
Efficacy failure at 6 months	18.7 <sup>b</sup>	16.8 <sup>c</sup>	32.3
<i>Components of efficacy failure</i>			
Biopsy-proven acute rejection	16.6	11.3	29.2
Graft loss	1.1	2.9	2.5
Death	0.7	1.8	0
Lost to follow-up	0.4	0.7	0.6

a: Patients received cyclosporine and corticosteroids

b: Rapamune 2 mg/day < Azathioprine (p = 0.002)

c: Rapamune 5 mg/day < Azathioprine (p < 0.001)

**Table -18: INCIDENCE (%) OF THE PRIMARY ENDPOINT AT 6 MONTHS: STUDY 2<sup>a</sup>**

	Rapamune Oral Solution 2 mg/day (n = 227)	Rapamune Oral Solution 5 mg/day (n = 219)	Placebo (n = 130)
Efficacy failure at 6 months	30.0 <sup>b</sup>	25.6 <sup>c</sup>	47.7
<i>Components of efficacy failure</i>			
Biopsy-proven acute rejection	24.7	19.2	41.5
Graft loss	3.1	3.7	3.9
Death	2.2	2.7	2.3
Lost to follow-up	0	0	0

a: Patients received cyclosporine and corticosteroids

b: Rapamune 2 mg/day < Placebo (p = 0.002)

c: Rapamune 5 mg/day < Placebo (p < 0.001)

Patient and graft survival at 1 year were secondary efficacy endpoints. The table below shows graft and patient survival at 1 year in Study 1 and Study 2. The graft and patient survival rates at 1 year were equivalent in the Rapamune-treated and comparator-treated patients.

**Table -19: 1 YEAR GRAFT AND PATIENT SURVIVAL (%)<sup>a</sup>**

	Rapamune Oral Solution 2 mg/day	Rapamune Oral Solution 5 mg/day	Azathioprine 2-3 mg/kg/day	Placebo
Study 1	(n = 284)	(n = 274)	(n = 161)	
Graft survival	94.7	92.7	93.8	
Patient survival	97.2	96.0	98.1	
Study 2	(n = 227)	(n = 219)		(n = 130)
Graft survival	89.9	90.9		87.7
Patient survival	96.5	95.0		94.6

a: Patients received cyclosporine and corticosteroids

The histological grade of the first biopsy-confirmed acute rejection in Study 1 and Study 2 was assessed using the Banff 1993 criteria as Grade I (mild), Grade II (moderate), and Grade III (severe). In the Rapamune 2 and 5 mg/day treatment groups, the incidence of moderate and severe graded rejection episodes was lower than the respective control groups.

In Study 1, which was prospectively stratified by race within centre, efficacy failure was similar for Rapamune oral solution 2 mg/day and lower for Rapamune oral solution 5 mg/day compared with azathioprine in black patients. In Study 2, which was not prospectively stratified by race, efficacy failure was similar for both Rapamune oral solution doses compared with placebo in black patients. The decision to use the higher dose of Rapamune oral solution in black patients must be weighed against the increased risk of dose-dependent adverse events that were observed with the Rapamune oral solution 5 mg dose (See ADVERSE REACTIONS).

**Table -20: PERCENTAGE OF EFFICACY FAILURE BY RACE AT 6 MONTHS**

		Rapamune Oral Solution 2 mg/day	Rapamune Oral Solution 5 mg/day	Azathioprine 2-3 mg/kg/day	Placebo
Study 1					
Black	(n=166)	34.9 (n=63)	18.0 (n=61)	33.3 (n=42)	
Non-black	(n=553)	14.0 (n=221)	16.4 (n=213)	31.9 (n=119)	
Study 2					
Black	(n=66)	30.8 (n=26)	33.7 (n=27)		38.5 (n=13)
Non-black	(n=510)	29.9 (n=201)	24.5 (n=192)		48.7 (n=117)

The table below shows the percentage of patients treated with antibody therapy for the first acute rejection episode in Study 1 and Study 2. There is a significantly lower incidence in the use of antibody therapy to treat first, biopsy-confirmed acute rejection in Rapamune-treated patients than in the comparator groups.

**Table -21: PERCENTAGE OF PATIENTS (%) TREATED WITH ANTIBODY THERAPY FOR FIRST ACUTE REJECTION EPISODE<sup>a</sup>**

Study	Rapamune 2 mg/day	Rapamune 5 mg/day	Azathioprine 2-3 mg/kg/day	Placebo
Study 1	(n = 284) 5.6 <sup>b</sup>	(n = 274) 2.9 <sup>c</sup>	(n = 161) 12.4	
Study 2	(n = 227) <sup>b</sup> 4.0 <sup>d</sup>	(n = 219) 3.2 <sup>e</sup>		(n = 130) 8.5

a: Patients received cyclosporine and corticosteroids

b: Rapamune 2 mg/day < Azathioprine (p = 0.017)

c: Rapamune 5 mg/day < Azathioprine (p < 0.001)

d: Rapamune 2 mg/day < Placebo (p = 0.094)

e: Rapamune 5 mg/day < Placebo (p = 0.044)

**Rapamune Tablets and Oral Solution – Clinical Equivalence Study:** The primary efficacy endpoint in Study 3 was the rate of efficacy failure in the first 3 months after transplantation. Efficacy failure was defined as the first occurrence of an acute rejection episode (confirmed by biopsy), graft loss, or death. The table below summarizes the results of the efficacy failure analysis at 3 and 6 months from this trial. The overall rate of efficacy failure at 3 months in the tablet treatment group was equivalent to the rate in the oral solution treatment group.

**Table -22: INCIDENCE (%) OF EFFICACY FAILURE AT 3 AND 6 MONTHS:  
STUDY 3<sup>a,b</sup>**

	Rapamune Oral Solution (n = 238)	Rapamune Tablets (n = 239)
<b>Efficacy failure at 3 months<sup>c</sup></b>	23.5	24.7
<i>Components of efficacy failure</i>		
Biopsy-proven acute rejection	18.9	17.6
Graft loss	3.4	6.3
Death	1.3	0.8
<b>Efficacy failure at 6 months</b>	26.1	27.2
<i>Components of efficacy failure</i>		
Biopsy-proven acute rejection	21.0	19.2
Graft loss	3.4	6.3
Death	1.7	1.7

a: Patients received cyclosporine and corticosteroids.

b: Includes patients who prematurely discontinued treatment.

c: Efficacy failure at 3 months was the primary endpoint.

Graft and patient survival at 12 months were co-primary endpoints. There were no significant differences between the oral solution and tablet formulations for both graft and patient survival. Graft survival was 92.0% and 88.7% for the oral solution and tablet treatment groups, respectively. The patient survival rates in the oral solution and tablet treatment groups were 95.8% and 96.2%, respectively.

#### **Rapamune without Concomitant Cyclosporine Administration (Study 4)**

**Rapamune Maintenance Regimen (RMR):** The primary efficacy endpoint was graft survival at 12 months after transplantation in Study 4. Secondary efficacy endpoints were the rate of biopsy-confirmed acute rejection, patient survival, incidence of efficacy failure (defined as the first occurrence of either biopsy-proven acute rejection, graft loss, or death), and treatment failure (defined as the first occurrence of either discontinuation, acute rejection, graft loss, or death).

Based upon the analysis of data from 36 months and beyond, which showed a growing difference in graft survival and renal function, as well as significantly lower blood pressure in the cyclosporine withdrawal group, it was decided by the sponsor to discontinue subjects from the Rapamune with cyclosporine group. When the protocol was amended all subjects had reached 48 months and some completed the 60 months of the study.

The table below summarizes the resulting graft and patient survival at 12, 24, 36, 48 and 60 months for this trial. At 48 months, there was a statistically significant difference in graft

survival between the two groups for both analyses (including and excluding loss to follow-up), although at 12, 24, 36 and 60 months, graft and patient survival were similar for both groups.

**Table -23: GRAFT AND PATIENT SURVIVAL (%): STUDY 4<sup>a</sup>**

Parameter	Rapamune with Cyclosporine Therapy (n = 215)	Rapamune Following Cyclosporine Withdrawal (n = 215)
<b>Graft Survival</b>		
Month 12 <sup>b</sup>	95.3 <sup>c</sup> [95.3] <sup>d</sup>	97.2 [97.2]
Month 24	91.6 [91.6]	94.0 [94.0]
Month 36 <sup>e</sup>	87.0 [88.4]	91.6 [92.6]
Month 48	75.3 [84.2]	86.0 [91.2]
Month 60	67.9 [83.3]	80.0 [88.4]
<b>Patient Survival</b>		
Month 12	97.2 [97.2]	98.1 [98.1]
Month 24	94.4 [94.9]	95.8 [96.3]
Month 36 <sup>e</sup>	91.6 [94.4]	94.0 [96.3]
Month 48	78.6 [91.6]	86.5 [95.3]
Month 60	68.8 [90.2]	80.9 [93.0]

a: Includes patients who prematurely discontinued treatment.

b: Primary efficacy endpoint.

c: Survival including loss to follow up as an event.

d: Survival excluding loss to follow up as an event.

e: Initial planned duration of the study.

The table below summarizes the incidence of first biopsy-proven acute rejection at 12 and 60 months. There was a significant difference in the incidence of first biopsy-proven acute rejection between the two groups during post-randomization through 12 months. However at month 60, the difference between the two groups was not significant (6.5% vs. 10.2%, respectively). Most of the post-randomization acute rejections occurred in the first 3 months following randomization.

**Table -24: INCIDENCE OF FIRST BIOPSY-PROVEN ACUTE REJECTION (%) BY TREATMENT GROUP AT 60 MONTHS: STUDY 4<sup>a</sup>**

Period	Rapamune with Cyclosporine Therapy (n=215)	Rapamune Following Cyclosporine Withdrawal (n=215) <sup>c</sup>	p-Value <sup>d</sup>
Pre-randomization <sup>b</sup>	9.3	10.2	NS
Post-randomization through 12 months <sup>b</sup>	4.2	9.8	0.036
Post-randomization from 12 months to 60 months	2.3	0.4	NS
Post-randomization through 60 months	6.5	10.2	NS
Total at 60 months	15.8	20.5	NS

a: Includes patients who prematurely discontinued treatment.

b: Randomization occurred at 3 months ± 2 weeks after transplantation.

c: Cyclosporine was withdrawn over a 6 week period after randomization.

d: Rapamune with cyclosporine therapy versus Rapamune following cyclosporine withdrawal.

NS: Not significant.

At 24 and 36 months, patients receiving renal allografts with >3 HLA mismatches experienced significantly higher rates of acute rejection following randomization to the cyclosporine withdrawal group compared with patients who continued cyclosporine (15.3% vs 3.0%). This difference was no longer statistically significant at months 48 and 60 (15.3% vs 6.0%). Patients receiving renal allografts with ≤3 HLA mismatches demonstrated similar rates of acute rejection between treatment groups throughout the course of the trial, with an incidence of (6.8% vs 7.7%) at month 60 following randomization.

The table below summarizes the mean calculated GFR in Study 4.

**Table -25: CALCULATED GLOMERULAR FILTRATION RATES (mL/min) BY NANKIVELL EQUATION AT 12, 24, 36, 48 AND 60 MONTHS POST TRANSPLANT: STUDY 4<sup>a,b</sup>**

Parameter	Rapamune with Cyclosporine Therapy	Rapamune Following Cyclosporine Withdrawal
Month 12		
Mean ± SEM	53.2 ± 1.5 n=208	59.3 ± 1.5 <sup>c</sup> n=203
Month 24		
Mean ± SEM	48.4 ± 1.7 n=203	58.4 ± 1.6 <sup>c</sup> n=201
Month 36		
Mean ± SEM	47.0 ± 1.8 n=196	58.5 ± 1.9 <sup>c</sup> n=199

**Table -25: CALCULATED GLOMERULAR FILTRATION RATES (mL/min) BY NANKIVELL EQUATION AT 12, 24, 36, 48 AND 60 MONTHS POST TRANSPLANT: STUDY 4<sup>a,b</sup>**

Month 48		
Mean ± SEM	43.5 ± 2.0 n=185	58.1 ± 2.0 n=187
Month 60		
Mean ± SEM	42.7 ± 2.2 n=176	58.0 ± 2.1 n=193

a: Includes patients who prematurely discontinued treatment.

b: Patients who had a graft loss were included in the analysis and had their GFR set to 0.0.

c: Analysis of covariance  $p < 0.001$  for Rapamune with cyclosporine therapy versus Rapamune following cyclosporine withdrawal.

The mean GFR at 12, 24, 36, 48 and 60 months, calculated by the Nankivell equation, was significantly higher for patients receiving Rapamune as a maintenance regimen than for those in the Rapamune plus cyclosporine therapy group. At month 60, patients with an acute rejection at any time after transplantation had a significantly higher mean calculated GFR for patient receiving Rapamune as a maintenance regimen following cyclosporine withdrawal compared to those in the Rapamune with cyclosporine group. At 36 months among patients with serial biopsies (n=63), the mean Chronic Allograft Damage Index (CADI) score was significantly lower for patients receiving Rapamune as a maintenance regimen than for those in the Rapamune plus cyclosporine therapy group (3.20 vs. 4.70,  $p=0.003$ ), as was the mean tubular atrophy score (0.32 vs. 0.77,  $p=0.001$ ).

The Banff 1993 classification was used in this study. After a posteriori review of the Banff grading criteria, it seems unlikely that the results of the present trial would have changed by using a more recent classification (See References 14,15).

### **Rapamune with Cyclosporine Administration (Study 5)**

**High-Risk Patients Study:** A total of 224 patients received a transplant and at least one dose of sirolimus and cyclosporine and was comprised of 77.2% Black patients, 24.1% repeat renal transplant recipients, and 13.5% patients with high PRA. Efficacy was assessed with the following endpoints, all measured at 12 months: efficacy failure (defined as the first occurrence of biopsy-confirmed acute rejection, graft loss, or death), first occurrence of graft loss or death, and renal function as measured by the calculated GFR using the Nankivell formula. The table below summarizes the results of these endpoints.

**Table -26: EFFICACY FAILURE, GRAFT LOSS OR DEATH AND CALCULATED GLOMERULAR FUNCTION RATES (mL/min) BY NANKIVELL EQUATION AT 12 MONTHS POST TRANSPLANT: STUDY 5**

Parameter	Rapamune with Cyclosporine, Corticosteroids (n = 224)
Efficacy Failure (%)	23.2
Graft Loss or Death (%)	9.8
Renal Function (mean ± SEM) <sup>a, b</sup>	52.6 ± 1.6 (n = 222)

a: Calculated glomerular filtration rate by Nankivell equation

b: Patients who had graft loss were included in this analysis with GFR set to 0.

Patient survival at 12 months was 94.6%. The incidence of biopsy-confirmed acute rejection was 17.4% and the majority of the episodes of acute rejection were mild in severity.

### Comparative Bioavailability Studies

**Rapamune Tablets:** Bioequivalence of the 2 mg and 5 mg tablet strengths was established versus the 1 mg tablet. The study was a single-dose, open-label, randomized, 3-period crossover study in 24 healthy subjects. When subjects were randomly assigned to receive equimolar doses of 10 mg sirolimus during each period as either ten 1 mg tablets (reference product), five 2 mg tablets, or two 5 mg triangular tablets, peak exposure ( $C_{max}$ ) and total exposure ( $AUC_t$  and  $AUC$ ) remained equivalent. The exception was that  $t_{max}$  was longer for the 5 mg tablets compared with the other tablets. A summary of the results of the study are presented in the following tables:

**Table -27: SUMMARY TABLE OF COMPARATIVE BIOAVAILABILITY DATA  
SIROLIMUS (5 X 2 MG)  
From measured and log transformed data  
Geometric Mean  
Arithmetic Mean (CV %)**

Parameter	Test*	Reference <sup>†</sup>	% Ratio of GLS <sup>#</sup> Means	90% Confidence Interval
$AUC_{0-72h}$ <sup>‡</sup> (ng·h/mL)	487	476	103	96-110
	503 (26.3)	487 (21.7)		
$AUC_{0-4}$ (ng·h/mL)	767	742	104	98-110
	792 (26.8)	765 (24.9)		

**Table -27: SUMMARY TABLE OF COMPARATIVE BIOAVAILABILITY DATA****SIROLIMUS (5 X 2 MG)****From measured and log transformed data****Geometric Mean****Arithmetic Mean (CV %)**

<b>Parameter</b>	<b>Test*</b>	<b>Reference†</b>	<b>% Ratio of GLS# Means</b>	<b>90% Confidence Interval</b>
$C_{MAX}$ (ng/mL)	21.2 22.4 (33.0)	22.8 23.6 (27.8)	93	84-102
$T_{MAX}^{\S}$ (h)	2.82 (94.0)	2.55 (69.4)		
$T_{1/2}^2$ (h)	63.5 (14.4)	66.6 (18.2)		

\* Rapamune five 2 mg Tablets.

† Rapamune ten 1 mg Tablets, Wyeth Pharmaceuticals, Canada.

§ Expressed as the arithmetic mean (CV%) only.

2 Expressed as the arithmetic mean (CV%) only.

# GLS= geometric least squares. All estimates of the GLS mean ratios were based on log-transformed data except  $t_{max}$ , which was untransformed**Table -28: SUMMARY TABLE OF COMPARATIVE BIOAVAILABILITY DATA****SIROLIMUS (2 X 5 MG)****From measured and log transformed data****Geometric Mean****Arithmetic Mean (CV %)**

<b>Parameter</b>	<b>Test*</b>	<b>Reference†</b>	<b>% Ratio of GLS# Means</b>	<b>90% Confidence Interval</b>
$AUC_{0-72h}^{\ddagger}$ (ng·h/mL)	535 551 (25.1)	476 487 (21.7)	113	106-119
$AUC_{0-4}$ (ng·h/mL)	837 866 (27.8)	742 765 (24.9)	113	106-120
$C_{MAX}$ (ng/mL)	20.1 20.8 (28.8)	22.8 23.6 (27.8)	88	80-96
$T_{MAX}^{\S}$ (h)	4.14 (68.1)	2.55 (69.4)		
$T_{1/2}^2$ (h)	65.7 (17.7)	66.6 (18.2)		

\* Rapamune two 5 mg Tablets.

† Rapamune ten 1 mg Tablets, Wyeth Pharmaceuticals, Canada.

§ Expressed as the arithmetic mean (CV%) only.

2 Expressed as the arithmetic mean (CV%) only.

# GLS= geometric least squares. All estimates of the GLS mean ratios were based on log-transformed data except  $t_{max}$ , which was untransformed

## Pediatric Study

Rapamune was evaluated in a 36-month, open-label, randomized, controlled clinical trial at 14 North American centres in pediatric (aged 3 to <18 years) renal transplant recipients considered to be at high immunologic risk for developing chronic allograft nephropathy, defined as a history of one or more acute allograft rejection episodes and/or the presence of chronic allograft nephropathy on a renal biopsy. Seventy-eight (78) subjects were randomized in a 2:1 ratio to Rapamune (sirolimus target concentrations of 5 to 15 ng/mL, by chromatographic assay, n=53) in combination with a calcineurin inhibitor and corticosteroids or to continue calcineurin-inhibitor-based immunosuppressive therapy (n=25). The primary endpoint of the study was efficacy failure as defined by the first occurrence of biopsy confirmed acute rejection, graft loss, or death, and the trial was designed to show superiority of Rapamune added to a calcineurin-inhibitor-based immunosuppressive regimen compared to a calcineurin inhibitor-based regimen. The cumulative incidence of efficacy failure up to 36 months was 45.3% in the Rapamune and calcineurin inhibitor group compared to 44.0% in the control group, and did not demonstrate superiority. There was one death in each group. The use of Rapamune in combination with calcineurin inhibitors and corticosteroids was associated with an increased risk of deterioration of renal function, serum lipid abnormalities (including but not limited to increased serum triglycerides and cholesterol), and urinary tract infections. This study does not support the addition of Rapamune to calcineurin-inhibitor-based immunosuppressive therapy in this subpopulation of pediatric renal transplant patients.

**De novo use without calcineurin inhibitor (CNI):** In two multi-center clinical studies, de novo renal transplant patients treated with Rapamune, MMF, corticosteroids, and an IL-2 receptor antagonist had significantly higher acute rejection rates and numerically higher death rates compared to patients treated with a calcineurin inhibitor, MMF, corticosteroids, and IL-2 receptor antagonist. A benefit, in terms of better renal function, was not apparent in the treatment arms with de novo use of Rapamune without a CNI. It should be noted that an abbreviated schedule of administration of daclizumab was employed in one of the studies (See WARNINGS AND PRECAUTIONS).

## DETAILED PHARMACOLOGY

Sirolimus (Rapamune, Rapamycin) is a macrocyclic natural product produced by *Streptomyces hygroscopicus* that was initially identified as an antifungal agent. Further pharmacological evaluation revealed its immunosuppressive activity in a rat model of T cell-mediated autoimmune disease. Additional *in vitro* and *in vivo* pharmacology studies demonstrated that

sirolimus was a potent immunosuppressive and antiproliferative agent that prevents allograft rejection in virtually all animal models of organ transplantation.

The macrocyclic immunosuppressive agents, including sirolimus, cyclosporine, and tacrolimus, bind to specific cytosolic proteins called immunophilins to generate an immunosuppressive complex. The complex of cyclosporine or tacrolimus with their respective immunophilins (cyclophilin and FK binding protein [FKBP12]) inhibits calcineurin, a Ca<sup>++</sup>/calmodulin-dependent serine/threonine phosphatase required for the production of cytokines, specifically interleukin-2 (IL-2) and early activation of T cells (G0 to G1). However, the mechanism of action of sirolimus is distinct from that of cyclosporine and tacrolimus. Although sirolimus also binds to FKBP12, in contrast to tacrolimus the sirolimus:FKBP complex has no effect on calcineurin activity. Rather, this complex binds to a specific cell cycle regulatory protein called the mammalian Target Of Rapamycin (mTOR) and inhibits its activation. The inhibition of mTOR suppresses cytokine-driven (IL-2, IL-4, IL-7 and IL-15) T-cell proliferation, inhibiting the progression from G1 to S phase of the cell cycle. mTOR is a key regulatory kinase and its inhibition by sirolimus has several related effects. These include: 1) inhibition of translation of a family of mRNAs that code for proteins essential for cell cycle progression; 2) inhibition of IL-2-induced transcription of proliferating cell nuclear antigen (PCNA) that is essential for DNA replication; 3) block of CD28-mediated sustained upregulation of IL-2 transcription in T cells; and, 4) inhibition of the kinase activity of the cdk4/cyclin D and cdk2/cyclin E complexes causing decreased synthesis of cell cycle proteins cdc2 and cyclin A, essential for cell cycle progression.

Thus, sirolimus blocks G1 to S cell cycle progression by inhibiting signal transduction, via a specific target protein. Its mechanism of action is distinct from cyclosporine and tacrolimus because it does not act via the calcineurin pathway. It is also different from other immunosuppressive drugs that act solely by inhibiting DNA synthesis such as mycophenolate mofetil and azathioprine.

After PO administration, the bioavailability of sirolimus was low in rats (1.9%) and monkeys (3.7%), due to significant first-pass metabolism by liver and intestinal wall, as well as poor absorption. The pharmacokinetics of sirolimus were generally linear, except at the highest toxicological doses, and no accumulation of sirolimus occurred following chronic oral administration. After IV administration, the sirolimus clearance and V<sub>d<sub>ss</sub></sub> in whole blood (WB) were lower than the corresponding values in plasma, as a result of sirolimus distribution into red blood cells. Species differences in WB/plasma distribution were observed, with WB/plasma

ratios following the order: human  $\geq$  monkey > pigs  $\geq$  rabbits > rats > mice. In all species, sirolimus was extensively metabolized and the metabolites were primarily excreted via the bile into the feces. Circulating metabolites retained 30% or less of the total potency of sirolimus in the thymocyte proliferation assay. Cytochrome P<sub>450</sub> IIIA was identified as the major cytochrome P<sub>450</sub> responsible for the metabolism of sirolimus and there was no evidence that sirolimus causes induction of rat hepatic CYP<sub>450</sub> enzymes. Urinary excretion is minor, indicating that renal dysfunction would have little effect on elimination.

Ancillary pharmacology studies demonstrated that sirolimus had no significant effects on CNS, cardiovascular, or GI systems, and the studies support the specific activity of sirolimus in immune cells.

## **TOXICOLOGY**

### **Acute Toxicology**

The single-dose toxicity profile of sirolimus was evaluated in PO and IV studies in mice and rats.

Sirolimus elicited a relatively low order of acute toxicity. In PO studies, death occurred in one of 10 mice after administration of 500 mg/kg; however, no deaths occurred in mice or rats at the maximum feasible dosage of 800 mg/kg. Compound-related clinical signs in PO studies included decreased motor activity, ptosis, and rough hair coat in both mice and rats, and red pigmentation around the nose or mouth in rats.

In IV studies, mortality occurred in one of 10 mice and three of 10 rats at the maximum feasible dosage of 250 mg/kg (and the only dosage tested in rats). Compound-related clinical signs in IV studies included focal tail (injection site) abrasions in both mice and rats, ptosis and low carriage in mice, and immobility, ataxia, tachypnea and decreased motor activity in rats.

The clinical signs observed were typical for acute studies in rodents and no unexpected toxicities were demonstrated.

### **Chronic Toxicology**

The repeated-dose toxicity profile of sirolimus was evaluated in PO studies in rats for up to 1 year (with a 1- and 3-month recovery period in the 3- and 6-month studies, respectively), and in monkeys for up to 6 months (with a 3-month recovery period in the 6-month study), and in IV

studies in rats and monkeys for up to 1 month. Six repeated-dose toxicity studies were conducted in beagle dogs, with administration of sirolimus by the PO, IV, or intravaginal routes for up to 1 month. However, systemic vasculitis and ulceration of the alimentary tract epithelia precluded the use of dogs to further characterize the toxicity profile of sirolimus. Repeated-dose PO toxicity studies in mice were conducted to establish doses for the carcinogenicity studies. The routes of administration and dosage ranges used in these studies are summarized in the table below:

**Table -29: SUMMARY OF REPEATED-DOSE TOXICITY STUDIES**

Species	Route of Administration	Dosage Range (mg/kg/day)
Rat/Crl:CD	PO	0.025 – 10
	IV	0.025 – 5
Dog (beagle)	PO	0.025 - 10, and 200 mg capsule
	IV	0.025 – 10
	Intravaginal	20 - 200 mg capsule
Monkey/Cynomolgus	PO	0.05 – 25
	IV	0.025 – 10

The following table summarizes the major toxicology findings by dosage in rat and monkey:

**Table -30: MAJOR COMPOUND-RELATED FINDINGS IN REPEATED-DOSE ORAL TOXICITY STUDIES IN RATS AND MONKEYS ADMINISTERED SIROLIMUS**

Findings	Dosages Evaluated (mg/kg/day)	LOEL (mg/kg/day)	NOEL (mg/kg/day)
<b>Rats</b>			
Bone Loss (Lameness)			
3-Month Study			
Male	0.05 to 5	5	2
Female	0.05 to 5	Not Observed	>5
1-Year Study	0.2 to 6	0.2	NA
Hematopoiesis (Liver, Spleen) and Hemosiderosis (Kidney, Lung, Lymph Node, Spleen)			
1-Year Study	0.2 to 6	0.2	NA
Lymphoid/Thymic Atrophy			
1-Month Studies	0.05 to 5	0.25	0.1
1-Year Study	0.2 to 6	0.65	0.2

**Table -30: MAJOR COMPOUND-RELATED FINDINGS IN REPEATED-DOSE ORAL TOXICITY STUDIES IN RATS AND MONKEYS ADMINISTERED SIROLIMUS**

Findings	Dosages Evaluated (mg/kg/day)	LOEL (mg/kg/day)	NOEL (mg/kg/day)
<b>Rats</b>			
Myocardial Degeneration			
1-Month Studies	0.05 to 5	1	0.25
3- and 6-Month Studies	0.05 to 5	0.1	0.05
1-Year Study	0.2 to 6	0.65	0.2
Ovarian Atrophy			
1-Year Study	0.2 to 6	0.2	NA
Pancreatic Islet Cell Vacuolation			
1-Month Studies	0.05 to 5	0.25	0.1
3-Month Study	0.5 to 5	2	0.5
1-Year Study	0.2 to 6	0.65	0.2
Pulmonary Alveolar Macrophages			
1-Month Studies	0.05 to 5	1	0.25
3-Month Study	0.5 to 5	0.5	NA
1-Year Study	0.2 to 6	0.2	NA
Testicular Tubular Atrophy/Degeneration			
3-Month Study	0.5 to 5	2	0.5
1-Year Study	0.2 to 6	0.65	0.2
<b>Monkeys</b>			
Colitis			
3- and 6-Month Studies	0.5 to 10	0.25	0.05
Lymphoid/Splenic/Thymic Atrophy			
1-Month Studies	0.05 to 15	0.25	0.1
3- and 6-Month Studies	0.05 to 10	0.25	0.1

LOEL = Lowest-observable-effect level; NA= Not applicable (finding occurred at all dosages in study);  
NOEL = No-observable-effect level

In repeated-dose studies in mice, rats, dogs, and monkeys, many of the compound-related findings were attributable to the immunosuppressive effect of sirolimus, and have been seen with other compounds of this class, such as cyclosporine and tacrolimus.

### **Carcinogenicity, Mutagenesis, and Impairment of Fertility**

Sirolimus was not mutagenic in the *in vitro* bacterial reverse mutation assay, the Chinese hamster ovary cell chromosomal aberration assay, the mouse lymphoma cell forward mutation assay, or the *in vivo* mouse micronucleus assay.

Carcinogenicity studies were conducted in female mice and male and female rats. In the 86-week female mouse study at dosages of 0, 12.5, 25 and 50/6 mg/kg/day (dosage lowered from 50

to 6 mg/kg/day at week 31 due to infection secondary to immunosuppression) there was a statistically significant increase in malignant lymphoma at all dosages (approximately 86 to 357 times the maximum recommended human dose [MRHD]) compared to controls. In the 104-week rat study at dosages of 0, 0.05, 0.1, and 0.2 mg/kg/day, there was an increased incidence of testicular adenoma in the 0.1 and 0.2 mg/kg/day (approximately 1.4 to 2.9 times the MRHD) groups.

There was no effect on fertility in female rats following the administration of sirolimus at dosages up to 0.5 mg/kg (approximately 7 times the MRHD). In male rats, there was no significant difference in fertility rate compared to controls at a dosage of 2 mg/kg (approximately 28 times the MRHD). Reductions in testicular weights and/or histological lesions (e.g., tubular atrophy and tubular giant cells) were observed in rats following dosages of 0.65 mg/kg (approximately 9 times the MRHD) and above and in a monkey study at 0.1 mg/kg (approximately 1.4 times the MRHD) and above. Sperm counts were reduced in male rats following the administration of sirolimus for 13 weeks at a dosage of 6 mg/kg (approximately 85 times the MRHD), but showed improvement by 3 months after dosing was stopped.

### **Pregnancy**

Pregnancy Category C: Sirolimus was embryo/fetal toxic in rats at dosages of 0.1 mg/kg and above (approximately 1.4 times the MRHD). In animal studies, embryo/fetal toxicity was manifested as mortality and reduced fetal weights (with associated delays in skeletal ossification). However, no teratogenesis was evident. There were no effects on rabbit development at the maternally toxic dosage of 0.05 mg/kg (approximately 0.7 times the MRHD).

There are no adequate and well controlled studies of Rapamune use in pregnant women. Consequently, Rapamune should be used during pregnancy only if the potential benefit outweighs the potential risk to the embryo/fetus.

## REFERENCES

1. Huston EE, Li Y, Goldberg-Alberts R, et al. A double-blind, comparative study of the effect of two dose levels of sirolimus versus azathioprine, administered concomitantly with standard immunosuppressive therapy in renal allograft recipients: 24-Month final report (protocol 0468E1-301-US). Data on file, Wyeth Canada.
2. Reilly TM, Goldberg-Alberts R, Wang F, et al. A placebo-controlled, double-blind study of the effect of two dose levels of sirolimus plus standard immunosuppressive therapy in renal allograft recipients: 36-month final report (protocol 0468E1-302-GL). Data on file, Wyeth Canada.
3. Fawl R, Guttman RM, Crouse W, et al. A comparative study of the effect and equivalence of sirolimus oral liquid versus sirolimus tablets, administered concomitantly with cyclosporine and corticosteroids in renal allograft recipients: 12-month final report (Protocol 0468H1-309-GL). Data on file, Wyeth Canada.
4. Foehl JR, Huston EE, Brault Y, et al. A randomized, open-label study of continuous therapy with cyclosporine and sirolimus versus induction with cyclosporine and sirolimus followed by continuous therapy with sirolimus in renal allograft recipients: 24-month interim report. (Protocol 0468H1-310-GL). Data on file, Wyeth Canada.
5. Rapamune 3-Year Safety Update: Renal Transplant Recipients in Study 0468H1-310-GL. Data on file, Wyeth Canada.
6. Zimmerman JJ, Rueter S, Parks V. A comparative bioavailability study of ten 1-mg, five 2-mg and two 5-mg triangular tablets of sirolimus in healthy subjects: final report (Protocol 0468H1-187-UK). Data on file, Wyeth Canada.
7. Arceci RJ, Stieglitz K, Bierer BE. Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. *Blood* 1992; 80(6):1528-36.
8. Crowe A, Lemaire M. *In vitro* and *in situ* absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison with rapamycin. *Pharm Res* 1998;15(11):1666-72.
9. Maltz HC, Balog DL, Cheigh JS. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine. *Ann Pharmacother* 1999; 33(11):1176-9.
10. Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, et al. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. *Drug Metab Dispos* 1997; 25(11):1228-33.
11. Shaw LM., ed. Advances in therapeutic drug monitoring for immunosuppressants: A review of sirolimus. *Clin Ther* 2000;22 Suppl B:B1-B132.

12. Vanholder R, Sever MS, Ereik E, et al. Rhabdomyolysis. *J Am Soc Nephrol* 2000;11: 1553-1561.
13. Wachter VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and p-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. *Mol Carcinog* 1995;13:129-34.
14. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. *Kidney Int* 55: 713, 1999.
15. Racusen LC, Colvin RB, Solez K et al. Antibody-mediated rejection criteria- an addition to the Banff '97 classification of renal allograft rejection. *Am J Transplant* 3:708, 2003.
16. Hariharan S, McBride MA, Cherikh WS, et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. *Kidney Int* 2002;62:311-318.
17. Nankivell BJ, Borrows RJ, Fung, CLS, et al. The natural history of chronic allograft nephropathy. *N Engl J Med* 2003;349:2326-33.
18. Kahan BD, Kinight R, Schoenberg L, et al. Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience. *Transplant Proc* 2003;35 (Suppl 3A):25S-34S.
19. Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. *Transplantation* 2003;75:1291-1295.
20. Kreis H, Oberbauer R, Campistol JM, et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. *J Am Soc Nephrol* 2004;15:809-817.
21. Stallone G, Di Paolo S, Schena A, et al. Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus treated patients. *Transplantation* 2003;75:998-1003.
22. Oberbauer R, Kreis H, Johnson RWG, et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. *Transplantation* 2003;76:364-370.
23. Mota A, Arias M, Taskinen EI et al. Rapamune Maintenance Regimen Trial. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. *Am J Transplant* 2004;4(6):953-61.
24. Oberbauer R, Segoloni G, Campistol JM, et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. *Transplant Int* 2005;18:22-28.
25. Baboolal K. A phase III prospective, randomized study to evaluate concentration controlled sirolimus (Rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients. *Transplantation* 2003;75:1404-1408.

26. Johnson RWG, Kreis H, Oberbauer R, et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure *Transplantation* 2001;72:777–786.
27. Shaffer D, Langone A, Nylander WA, et al. A pilot protocol of a calcineurin-inhibitor free regimen for kidney transplant recipients of marginal donor kidneys or with delayed graft function. *Clin Transplant* 2003; 17 (Suppl. 9): 31–34.
28. Gonwa TA, Hricik DE, Brinker K, et al. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. *Transplantation* 2002;74: 1560–1567.
29. Campanero MA, Cardenas E, Sádaba B, et al. Therapeutic drug monitoring for sirolimus in whole blood of organ transplants by high-performance liquid chromatography with ultraviolet detection. *J. Chromatogr. A* 2004;1031:265-273.
30. Holt DW, McKeown DA, Lee TD, et al. The relative proportions of sirolimus metabolites in blood using HPLC with mass-spectrometric detection. *Transplant Proc* 2004;36:3223-3225.
31. Holt DW, Moreton M, Laamanen K, et al. A microparticle enzyme immunoassay to measure sirolimus. *Transplant Proc* 2005;37:182-184.
32. Rapamune 4-Year Safety Summary: Renal Transplant Recipients in Study 0468H1-310-GL. Data on file, Wyeth Canada.
33. Huston EE, Brault Y, et al. A randomized, open-label study of continuous therapy with cyclosporine and sirolimus versus induction with cyclosporine and sirolimus followed by continuous therapy with sirolimus in renal allograft recipients: 60-month final report (Protocol 0468H1-310-GL). Data on file, Wyeth Canada.
34. Zimmerman JJ, Matschke K, Huston EE. Pharmacokinetics of Sirolimus in Pediatric Renal Transplant Patients Receiving Either Concomitant Sirolimus and Cyclosporine or Concomitant Sirolimus and Tacrolimus Therapy (Protocols 0468E1-217-US and 0468H1-315-WW combined). Data on file, Wyeth Canada.
35. Huston EE, Goldberg-Alberts R, Zimmerman JJ, et al. An open-label, comparative study of the effect of sirolimus versus on standard treatment on clinical outcomes and histologic progression of allograft nephropathy in high risk pediatric renal transplant patients: interim report (Protocol 0468E1-217-US, CSR-52810). Data on file, Wyeth Canada.
36. Fawl R, Goldberg-Alberts R, Zimmerman JJ. A double-blind, comparative study of the effect of two dose levels of sirolimus versus azathioprine, administered concomitantly with standard immunosuppressive therapy in renal allograft recipients: 6-month report (Protocol 0468E1-301-US). Data on file, Wyeth Canada.

37. An open-label, concentration-controlled, randomized, 12 month study of Prograf, Rapamune, and corticosteroids compared to cyclosporine, USP (MODIFIED), Rapamune, and corticosteroids in high risk renal allograft recipients (protocol 0468H1-101164 [0468H1-903-US]). Wyeth CSR-61425, 2006. (Data on File, Wyeth Canada).
38. Meier-Kriesch H-U, Schold JD, Srinivas TR, Howard RJ et al. Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. *Am J Transplant* 2005;5:2273-2280.
39. Mendez R, Gonwa T, Yang HC, Weinstein S, et al. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: Results at 1 year. *Transplant* 2005;80(3):303-309.
40. Sehgal SN. Rapamune<sup>®</sup> (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. *Clin Biochem* 1998; 31(5):335-40.
41. Kradjan WA, Heart Failure. In: Koda-Kimble MA, Young LY, Kradjan WA, Guglielmo BJ eds. *Applied Therapeutics, The Clinical Use of Drugs*, 8<sup>th</sup> ed. Philadelphia, Pa: Lippincott Williams and Wilkins;2004:19:P36-37.
42. Stallone G, Infante B, DiPaolo S, et al. Sirolimus and angiotensin converting enzyme inhibitors together induce tongue oedema in renal transplant recipients. *Nephrol Dial Transplant*. 2004;19:2906-2908.
43. Burdese M, Rossetti M, Guarena C, et al. Sirolimus and ACE-inhibitors: A note of caution. *Transplantation*. 2005;79:251-252.
44. Bingham CO. Angioedema, in UpToDate, Rose BD, ed. UpToDate, Waltham, MA 2006.

## PART III: CONSUMER INFORMATION

### Pr **Rapamune**<sup>®</sup> (Sirolimus Oral Solution and Tablets)

This leaflet is part III of a three-part "Product Monograph" published when Rapamune was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about Rapamune. Contact your doctor or pharmacist if have any questions about the drug.

#### ABOUT THIS MEDICATION

##### What the medication is used for:

Rapamune belongs to a group of medicines called immunosuppressants. It is used to prevent your body from rejecting transplanted kidneys and is often used in combination with medicines called cyclosporine and corticosteroids.

##### What it does:

Rapamune is a drug that is used to help your body accept your transplanted kidney. In order to prevent rejection, Rapamune suppresses the body's natural immune system. When a patient receives an organ transplant, the body's white blood cells will try to get rid of (reject) the transplanted organ. Sirolimus works by preventing the white blood cells from getting rid of the transplanted organ.

##### When it should not be used:

- If you are allergic to sirolimus and any ingredient in Rapamune.

##### What the medicinal ingredient is:

Sirolimus (pronounced sih-ROW-lih-mus).

##### What the nonmedicinal ingredients are:

- Oral solution: Phosal 50 PG<sup>®</sup> (ascorbyl palmitate, ethanol, phosphatidyl-choline, propylene glycol, soybean oil fatty acids and sunflower mono and diglycerides) and Polysorbate 80.
- Tablets: Calcium sulfate anhydrous, carnauba wax, glyceryl monooleate, lactose monohydrate, magnesium stearate, microcrystalline cellulose, pharmaceutical glaze, polaxamer 188, polyethylene glycol 8000 powdered, polyethylene glycol type 20,000, povidone, vitamin E (*d,l*-alpha tocopherol), sucrose, talc, titanium dioxide and ink. In addition, the 2 mg tablet contains brown #70 iron oxide and yellow #10 iron oxide; the 5 mg tablet contains brown #75 iron oxide, and yellow #10 iron oxide.

##### What dosage form it comes in:

- Oral solution: 1 mg/mL.
- Tablet: 1 mg, 2 mg and 5 mg.

#### WARNINGS AND PRECAUTIONS

##### Serious Warnings and Precautions

- Rapamune may reduce the body's ability to fight infections.
- The development of cancer of the lymphoid tissues (called lymphoma) and skin may result from using immunosuppressants such as Rapamune.
- Cases of severe allergic reaction including skin reaction have been associated with Rapamune.

BEFORE you use Rapamune talk to your doctor or pharmacist if any of the following situations apply to you:

- Allergies: Tell your doctor if you have any allergies to medicines or any other substances such as foods, preservatives, or dyes.
- Pregnancy: Women must avoid pregnancy while taking Rapamune as it may cause damage to the unborn baby. Women must use effective contraception methods before taking Rapamune, during treatment with Rapamune and for 12 weeks after treatment has stopped. If you are unsure, or think you may become pregnant, talk to your doctor or pharmacist.
- Breast-feeding: It is not known whether Rapamune passes into breast milk. Ask your doctor or pharmacist for advice before breast-feeding your baby.
- Liver problems: You should inform your doctor if you have any liver problems or have had a disease which may have affected your liver, as this may affect the dose of Rapamune that you receive.
- If you have high cholesterol or triglycerides (fat in blood). Your doctor may order blood tests for you.
- If you are going to have an operation, or if you still have a wound that hasn't healed completely after a surgery, you should tell your doctor before receiving this medicine, as Rapamune may prevent these wounds from healing properly.
- Talk to your doctor before switching from the oral solution to the tablet, since your doctor may need to adjust the dose of Rapamune you receive.
- Limit your exposure to sunlight and UV light by wearing protective clothing and using a sunscreen with a high protection factor.
- Driving and operating machinery: No specific studies on the effects of Rapamune on the ability to drive and operate machines have been conducted. If you have any concerns please consult your doctor.
- Alcohol: Rapamune oral solution contains 1.5-2.5% ethanol. Each 2 mg dose contains up to 50 mg of alcohol, approximately the same amount of alcohol as half a teaspoon of a light beer. If you have any concerns please consult your doctor.
- Tell any other doctors, dentists, and pharmacists who are treating you that you are taking Rapamune.

## INTERACTIONS WITH THIS MEDICATION

### With drugs:

Some medicines and Rapamune may interfere with each other. Your doctor or pharmacist should know if you are taking, or have recently taken, other medicines, even those not prescribed for you, including non-prescription (over-the-counter) drugs and herbal preparations. Drugs that may interact with Rapamune include:

- Any other immunosuppressive agents.
- Antibiotics or antifungal medicines used to treat infection e.g. rifampicin, clarithromycin, erythromycin, telithromycin, troleandomycin, rifabutin, rifapentine, clotrimazole, fluconazole, itraconazole, ketoconazole, voriconazole.
- High blood pressure medicines or medicines for heart problems including nicardipine, verapamil and diltiazem.
- Anti-convulsant medicines including carbamazepine, phenobarbital, phenytoin.
- Cisapride (not marketed in Canada), metoclopramide, bromocriptine, cimetidine, danazol, protease inhibitors (eg, for HIV that include drugs such as ritonavir, indinavir, and hepatitis C drugs such as boceprevir, and telaprevir).
- Immunosuppressive drugs like Rapamune may alter the effectiveness of vaccinations. If you plan on being vaccinated, inform your doctor that you are taking Rapamune.
- Herbal preparations, such as St. John's Wort.

### With food:

- Grapefruit juice

These medicines/foods may be affected by Rapamune or may affect how well Rapamune works.

## PROPER USE OF THIS MEDICATION

- Rapamune is for oral use only.
- Your doctor will decide exactly what dose of Rapamune you must take and how often to take it.
- Your doctor may need to monitor the quantity of the drug in your blood.
- Always take the medicine exactly as your doctor tells you. Follow your doctor's instructions exactly and never change the dose yourself.
- Do not stop taking your medicine unless your doctor tells you to.

### Usual dose:

- Usually, for an adult, your doctor will give you an initial Rapamune dose of 6 mg at the time of your kidney transplant operation and then 2 mg each day.
- Your doctor may adjust your dose depending on your age, certain other medications which you may be taking, and/or the presence of other medical conditions. A lower dose may be required by elderly patients (older than 65 years).
- If you are also taking cyclosporine, Rapamune should be taken 4 hours after cyclosporine.
- Take Rapamune once a day at about the same time each day.
- Rapamune should be taken consistently, either with or without food.


- Do NOT take Rapamune with grapefruit or grapefruit juice.
- Do NOT take Rapamune after the expiry date printed on the container.
- If you are taking Rapamune tablets, do not crush, chew, or split the tablets. Inform your doctor if you have difficulty taking the tablet.
- After 2-4 months, your doctor may stop your dose of cyclosporine and increase your dose of Rapamune.
- If taking Rapamune oral solution, avoid contact with the skin, mucous membranes or eyes. In case of accidental contact with the skin, wash with soap and water. In case of eye contact, rinse with plain water.

### How to dilute Rapamune oral solution supplied in a bottle:

1. Open the solution bottle. Remove the safety cap by squeezing the tabs on the cap and twisting counterclockwise.




2. On first use, insert the adapter assembly (plastic tube with stopper) tightly into the bottle until it is even with the top of the bottle. Do not remove the adaptor assembly from the bottle once inserted.



3. For each use, tightly insert one of the amber syringes with the plunger fully depressed into the opening in the adapter.




4. Withdraw the prescribed amount of Rapamune oral solution by gently pulling out the plunger of the syringe until the bottom of the black line of the plunger is even with the appropriate mark on the syringe. Always keep the bottle in an upright position. If bubbles form in the syringe, empty the syringe into the bottle and repeat the procedure.



5. You may have been instructed to carry your medication with you. If it is necessary to carry the filled syringe, place a cap securely on the syringe - the cap should snap into place.



6. Then place the capped syringe in the enclosed carrying case. Once in the syringe, the medication may be kept at room temperature or refrigerated and should be used within 24 hours. Extreme temperatures below 2°C and above 30°C should be avoided.



7. Empty the syringe into a glass or plastic cup containing at least 2 ounces (¼ cup; 60 mL) of water or orange juice, stir vigorously for one (1) minute and drink immediately. Refill the container with at least 4 ounces (½ cup; 120 mL) of water or orange juice, stir vigorously again and drink the rinse solution. Apple juice, grapefruit juice, or other liquids are NOT to be used. Only glass or plastic cups should be used to dilute Rapamune oral solution. The syringe and cap should be used once and then discarded.



8. Always store the bottles of medication in the refrigerator. When refrigerated, a slight haze may develop in the solution. The presence of a haze does not affect the quality of the product. If this happens, bring the Rapamune oral solution to room temperature and shake until the haze disappears. If it is necessary to wipe clean the mouth of the bottle before returning the medication to the refrigerator, wipe with a dry cloth to avoid introducing water, or any other liquid into the bottle.



**Overdose:**

In case of drug overdosage, contact a healthcare professional (e.g. doctor), hospital emergency department, or regional poison control centre, even if there are no symptoms.

- Always take the labelled medicine bottle with you, even if it is empty.

**Missed Dose:**

If you forget to take Rapamune:

- If it is almost time for your next dose (within 4 hours), skip the dose you missed and take your next dose when you are meant to.
- Otherwise, take it as soon as you remember.
- After that, continue to take your medicine as usual.
- Do not take a double dose to make up for a forgotten dose, and always take Rapamune approximately 4 hours after cyclosporine.
- If you are not sure what to do, call your doctor or pharmacist.

**SIDE EFFECTS AND WHAT TO DO ABOUT THEM**

Like all medicines, Rapamune can have side effects. However, since Rapamune is taken in combination with other medicines, Rapamune may not have been the cause of the side effects experienced.

If you get any side effects, do not stop taking Rapamune without first talking to your doctor.

Tell your doctor if you have any of these symptoms and they concern you:

Very common side effects (occur in 10% or more of patients) include:

- Abnormal healing
- Abnormal vision
- Acne
- Constipation
- Diarrhea
- Headache
- Insomnia
- Joint, bone or back pain
- Nausea or upset stomach
- Stomach pain
- Swelling of the hands, feet, ankles, or lower legs
- Shaking (tremor)
- Urinary tract infection
- Weakness

Common side effects (occur in 1% to 9% of patients) include:

- Abnormal bleeding or bruising
- Cold or flu-like symptoms (lung infection)
- Dizziness upon standing
- Feeling anxious
- Fever or chills
- Fluid accumulation/retention

- Increased heart rate or heart palpitations
- Kidney infection
- Leg pain or muscle pain
- Menstrual disorders (Absence of menstrual period or abnormal heavy and prolonged menstrual period)
- Mouth ulcers or cold sores
- Nose bleed
- Ovarian Cysts
- Rash
- Shortness of breath
- Skin cancer
- Surgical wounds slow to heal
- Swollen abdomen

Uncommon or rare side effects (occur in less than 1% of patients) include:

- Melanoma (a type of skin cancer)
- Pancreatitis (inflammation of the pancreas)
- Severe allergic reaction including skin reaction

Unwanted side effects that you may not be aware of while taking your medicine include changes in levels of blood cells or substances in your blood (e.g. cholesterol, creatinine, or sugar). Your doctor may do blood tests to look for any changes.

Immunosuppressive drugs may increase the risk of infections.

Immunosuppressive drugs like Rapamune may increase your risk of developing lymphoma (a type of cancer) or cancer of the skin. Contact your doctor immediately if you notice a lump in your neck, armpits, collarbone region, or groin, or unintended weight loss (may be signs of lymphoma). Talk to your doctor if you notice any new moles or any changes in the size, shape, or colour of moles you already have (may be a sign of skin cancer).

Other side effects not listed above may also occur in some patients. Tell your doctor if you notice anything that concerns you, even if you do not think the problem is connected with Rapamune or the problem is not listed in this leaflet.

Do NOT stop taking Rapamune without talking to your doctor.

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM				
Symptom / effect		Contact your doctor or pharmacist immediately		Stop taking the drug and call your doctor or pharmacist immediately
		Only if severe	In all cases	
Very Common or Common	Bladder infection		√	
	Headache	√		
	Cough or shortness of breath		√	
	Increased heart rate		√	
	Isolated fever		√	

**SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM**

Symptom / effect	Contact your doctor or pharmacist immediately		Stop taking the drug and call your doctor or pharmacist immediately
	Only if severe	In all cases	
Sore throat, fever, chills, or swelling of glands Swelling of hands, feet, ankles or lower legs	Increased heart rate	√	√
Unusual bleeding or bruising		√	
Uncommon Possible signs of lymphoma: • Lump in your neck, armpits, collarbone region, or groin • Unintended weight loss		√	
	Coughing up blood		√
Rare Signs of severe allergic reaction. Signs may include: • Chest tightness • Dizziness • Faintness • Rapid heartbeat • Shortness of breath • Skin reaction • Swollen face, lips, or tongue • Wheezing			√

*This is not a complete list of side effects. For any unexpected effects while taking Rapamune contact your doctor or pharmacist.*

**HOW TO STORE IT**

- Keep Rapamune oral solution in its original container.
- Protect from light.
- Store oral solution at 2°C to 8°C, in a refrigerator for up to the expiration date indicated on the container label.
- Do NOT freeze.

- Once the bottle has been opened, the contents should be kept refrigerated and used within 30 days.
- If it is necessary to wipe clean the mouth of the bottle before returning the medication to the refrigerator, wipe with a dry cloth to avoid introducing water, or any other liquid into the bottle.
- When refrigerated the solution in the bottle may develop a slight haze. If this occurs, simply bring your Rapamune oral solution to room temperature and shake gently until the haze disappears. The presence of this haze does not affect the quality of Rapamune.
- If necessary, you may store bottles at 15°C to 30°C for a short time, but no longer than 5 days.
- Storage of Rapamune oral solution in capped syringe: Rapamune can only be stored refrigerated (2°C to 8°C) or at room temperatures (15°C to 30°C) for a maximum of 24 hours. The syringe should be discarded after one use. After dilution, preparation should be used immediately.
- Rapamune tablets should be stored at 15°C to 30°C for up to the expiration date indicated on the container label. Use cartons to protect blister cards from light.

Keep Rapamune oral solution and tablets out of reach of children.

**REPORTING SUSPECTED SIDE EFFECTS**

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

- Report online at [www.healthcanada.gc.ca/medeffect](http://www.healthcanada.gc.ca/medeffect)
- Call toll-free at 1-866-234-2345
- Complete a Canada Vigilance Reporting Form and:
  - Fax toll-free to 1-866-678-6789, or
  - Mail to: Canada Vigilance Program  
Health Canada  
Postal Locator 0701D  
Ottawa, Ontario  
K1A 0K9

Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada Web site at [www.healthcanada.gc.ca/medeffect](http://www.healthcanada.gc.ca/medeffect).

*NOTE: Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.*

**MORE INFORMATION**

This document plus the full Product Monograph, prepared for health professionals, can be found at: [www.pfizer.ca](http://www.pfizer.ca) or can be requested by contacting the sponsor, Pfizer Canada Inc., at 1-800-463-6001.

This leaflet was prepared by Pfizer Canada Inc.

Last revised: 25 October 2017